

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 097 944 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

09.05.2001 Bulletin 2001/19

(21) Application number: 99928210.6

(22) Date of filing: 06.07.1999

(51) Int. Cl.⁷: **C07K 16/18**, C12N 5/20,
C12P 21/08, G01N 33/53,
G01N 33/577, C12N 15/06

(86) International application number:
PCT/JP99/03656

(87) International publication number:
WO 00/02922 (20.01.2000 Gazette 2000/03)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 10.07.1998 JP 31209898

(71) Applicant:

FUSO PHARMACEUTICAL INDUSTRIES LTD.
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:

- Yamamoto, Hiroshi
Toyonaka-shi, Osaka 560-0054 (JP)
- Tsujikawa, Kazutake
Kawanishi-shi, Hyogo 666-0145 (JP)
- Uchino, Yukiko
Osaka-shi, Osaka 533-0004 (JP)

(74) Representative:

Dzieglewska, Hanna Eva
Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(54) **ANTIBODY AGAINST PROTEIN TYROSINE PHOSPHATASE INTRACELLULAR DOMAINS**

(57) Antibodies to intracellular domains of two or more kinds of protein tyrosine phosphatases, methods for generation thereof and cells producing these antibodies are disclosed. The antibody of the present invention may have specificity to intracellular domains of phosphatase subunits of both of LAR and CD45, and may be useful for analysis and quantitative determination of PTPs, identification and detection of novel PTPs, and for obtaining novel phosphatases by cloning and the like, as well as for developing useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onsets of arteriosclerosis and cardiac diseases.




Fig. 6

EP 1 097 944 A1

Description

FIELD OF THE INVENTION

- 5 **[0001]** The present invention relates to antibodies that specifically bind to intracellular domains of two or more kinds of protein tyrosine phosphatases (hereinafter referred to as PTPs) and to methods for generating the same. More particularly, the present invention relates to antibodies having specificity to intracellular domains of PTPs (e.g., LAR (leukocyte antigen related molecule) and CD45), which are useful for analysis and quantitative determination of PTPs, for identification, detection, and isolation and purification of novel PTPs, and for development of medical drugs applicable
10 to treatments such as therapy, prevention and alleviation as well as diagnosis of the disease states associated with insulin resistance.

BACK GROUND OF THE INVENTION

- 15 **[0002]** Mechanisms involving in the onset of arteriosclerosis have been gradually elucidated in these days, and risk factors thereof have been identified. Especially, hypercholesterolemia, hypertension, diabetes, and smoking are recognized to be manifest four risk factors, thus the therapeutic treatments have been extensively carried out. Clinically common pathology of these disease states is insulin resistance. The meaning of insulin resistance is nearly equivalent to the reduction of sensitivity to insulin in cells, and may be that the actions of insulin upon the uptake of sugar into the
20 cells are deteriorated. The insulin resistance may be caused due to the abnormalities in secretion of insulin itself, abnormalities of insulin receptors on target cells, abnormalities of an intracellular signaling system, and reduced supply of sugar to the tissue based on peripheral circulatory disorder that is caused hemodynamically. Reaven, in 1988, reported that many pathological states are developed due to the insulin resistance, and designates a pathological state as "syndrome X" that may concurrently represent insulin resistance, glucose tolerance abnormalities, hyperinsulinemia, hypertriglyceridemia, hypo-HDL cholesterolmia and hypertension, and further suggests that the pathological state
25 syndrome X closely participates in the onset of arteriosclerosis (Reaven, G. M. *et al.*, *Diabetes*, **37**, 1595-1607, 1988).
- [0003]** In addition, sugar supply to the cells is known to be generally decreased through insulin resistance, accompanied by enhancement of insulin secretion from pancreas, thus leading to hyperinsulinemia. Therefore, several problems in connection with insulin resistance have been raised in clinical fields. For example, insulin resistance and
30 hyperinsulinemia are reported to promote diabetic nephritis (Niskanen, L. *et al.*, *Diabetes*, **41**, 736-741, 1993), and to elevate frequency of diabetic retinopathy (Yip, J. *et al.*, *Lancet*, **341**, 369-370, 1993). Moreover, insulin resistance has been reported to enhance plasminogen activator inhibitor 1 (PAI-1), to deteriorate the functions of a blood fibrinolytic system (Potter van Loon BJ *et al.*, *Metab. Clin. Exp.*, **42**, 945-954, 1993), and to trigger arterial atherosclerosis (Sato, Y. *et al.*, *Diabetes*, **38**, 91-96, 1989).
- 35 **[0004]** Prevalence rate of diabetes accounts for 5% of the total population, and approximately six millions of Japanese citizens are suffering from diabetes. Diabetes comprises insulin dependent diabetic mellitus (IDDM) and non-insulin dependent diabetic mellitus (NIDDM). Reportedly, IDDM accounts for about 7% of the total diabetes cases, whilst NIDDM does about 90%. In particular, a significant causative factor of the onset of NIDDM that corresponds to a majority of diabetes has been conceived as the insulin resistance.
- 40 **[0005]** To date, tyrosine phosphorylation of intracellular proteins has been elucidated to play important roles in signal transduction of insulin. Insulin receptor is a hetero-tetramer of two glycoprotein subunits, namely an α -subunit having a molecular weight of 135 kDa and a β -subunit having a molecular weight of 95 kDa, which are bound through disulfide bonds resulting in a hetero tetramer having an $\alpha_2\beta_2$ structure. The α -subunit has an insulin binding activity, while the β -subunit has a protein tyrosine kinase (PTK) domain that is activated by autophosphorylation. Accordingly,
45 when insulin is bound to the α -chain of an insulin receptor, certain tyrosine residues existing in the β -chain of the insulin receptor are autophosphorylated by tyrosine kinase activity of the receptor. The activity of insulin receptor tyrosine kinase is further promoted through the tyrosine autophosphorylation. It is reported that thus activated insulin receptor tyrosine kinase phosphorylates tyrosine residues of IRS (insulin receptor substrate), the intracellular substrates thereof, and signal transduction is proceeded through recognition and binding of the tyrosine-phosphorylated insulin receptors
50 by Ash/Grb2 or PI-3 kinase, finally resulting in manifestation of biological activities of insulin, such as glucose uptake, sugar metabolism and cell proliferation (see, Fig. 9, Goldstein, B.J. *et al.*, *Receptor*, **3**, 1-15, 1993; and Kanai, F. *et al.*, *Biochemical and Biophysical Research Communications*, **195** (2), 762-768, 1993). In this signal transduction pathway, however, an enzyme that inactivates the activated insulin receptors, i.e., PTP, which is a protein tyrosine phosphatase, has not been progressively studied.
- 55 **[0006]** Moreover, fundamental mechanisms for lymphocyte activation, proliferation, differentiation, cell death and the like, which are also ingeniously controlled by tyrosine phosphorylation have not been likewise elucidated. Studies on signal transduction of lymphocyte in light of PTK have been mainstream of the studies so far, however, analyses from PTPs have also been performed, and importance of studies from both aspects have been manifested.

[0007] The serious studies of PTPs were initiated after completion of cloning of PTP1B gene and elucidation of the nucleotide sequence thereof by Fischer *et al.* in 1988, which is cytoplasm type PTP derived from human placenta (Tonks, N. K. *et al.*, *J. Biol. Chem.*, **263**, 6722-6730, 1988; Charbonneau, H. *et al.*, *Proc. Natl. Acad. Sci. USA*, **85**, 7182-7186, 1988). Consequently, homology to PTP1B could be observed not with the known serine/threonine phosphatases but with two cytoplasmic regions of CD45, a transmembranous molecule involved in a hemopoietic system. Moreover, CD45 was also revealed to have PTP activities (Tonks, N. K. *et al.*, *Biochemistry*, **27**, 8695-8701, 1988; and Charbonneau, H. *et al.*, *Proc. Natl. Acad. Sci. USA*, **85**, 7182-7186, 1988).

[0008] It is presumed that there are as many as 500 PTP genes in human, and to date, not less than 80 kinds of PTPs were cloned based on their homologies of cDNA sequences, while new PTPs have been still reported subsequently (Streuli, M. *et al.*, *J. Exp. Med.*, **168**, 1523-1530, 1988; Krueger, N. X. *et al.*, *EMBO J.*, **9**, 3241-3252, 1990; and Trowbridge, I. S. *et al.*, *Biochim. Biophys. Acta*, **1095**, 46-56, 1991). The PTPs that form a superfamily are broadly classified to three families. Namely, there are three groups, PTP, DS-PTP (dual-specificity-PTP) and LMW-PTP (low molecular weight-PTP). Homologies between primary structure of each of the family members are not that high, and in particular, no homology was suggested between PTP and LMW-PTP except for the homology of both enzymatic active centers, however, based on the studies on crystallography, it was illustrated that the molecules belonging to these families exhibit surprisingly common characters in their tertiary structures (Fauman, E. B. *et al.*, *Trends Biochem. Sci.*, **21**, 413-417, 1996). Furthermore, PTPs can be classified generally to: (1) receptor type (or, membrane type) PTPs having transmembrane region (LCA, leukocyte common antigen, namely CD45, LAR and PTPs α , β , γ , δ , ϵ and ζ); and (2) cytoplasm type PTPs without transmembrane region (PTP1B, TC-PTP, PTP-MEG, PTPH1, STEP, PTP1C, FAP1, SHP1, SHP2, PEP, PTP-PEST and the like).

[0009] Many of receptor type PTPs have two PTP homologous domains inside the cell (domain 1 and domain 2, see, Fig. 1(a) and (b)). A sequence comprising cysteine (signature motif), Ile/Val-His-Cys-Xaa-Ala-Gly-Xaa-Xaa-Arg-Ser/Thr-Gly (SEQ ID NO: 2), has been conserved in the phosphatase domains between the PTPs reported heretofore. The researches on crystallography of PTP1B revealed that the region forms small pockets on the surface of a PTP molecule, and that the cysteine residue is located to the bottom of the pocket, participating directly in binding of the molecule to phosphate (Barford, D. *et al.*, *Science*, **263**, 1397-1404, 1994). In addition, it was also revealed that the depth of the pocket of PTP may determine the specificity of serine/threonine phosphatase because phosphate that is binding to serine or threonine cannot reach to the pocket of the enzymatic active center of PTP1B. Moreover, the importance of the above-mentioned signature motif in exhibiting the enzymatic activity has been elucidated from experiments of the mutants (Streuli, M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990). Taking into account of these observations, it has been conceived that the conserved cysteine in domain 1 may play an important role in exhibiting the enzymatic activity, and domain 2 may determine the substrate specificity of the enzyme.

[0010] Receptor type PTPs have two or one intracellular enzymatic region(s), and they can be classified to several groups in accordance with their properties of extracellular domains. There are: CD45 having one extracellular fibronectin type III domain and being highly modified with sugar chains; LAR, PTP δ and PTP ϵ having Ig-like domains and fibronectin type III domains; PTP μ and PTP κ having MAM (meprin, A5 antigen, PTP μ) at N-terminal ends; PTP γ and PTP ζ having a carbonate dehydratase domain at N-terminal ends; and PTP α and PTP ϵ having short extracellular domains, and any of these PTPs has two enzymatic regions. Meanwhile, any of PTPs having single enzymatic region for example, PTP β , and CD148 (PTP η , DEP-1 and the like), is constituted from only fibronectin type III domains in its extracellular domain.

[0011] Cytoplasm type PTPs have one enzymatic region in principle, and have been classified to several groups based on their properties of non-enzymatic regions. Cytoplasm type PTPs may have SH2 region, PEST region, and band 4.1 region. DS-PTPs are enzymes that dephosphorylate serine or threonine as well as tyrosine residue, which may include Cdc25, MAP kinase phosphatase, VH-1 and the like. LMW-PTP is constituted from an enzymatic region alone, and its molecular weight is reported to be about 18 kDa.

[0012] Among the groups of PTPs, LAR derived from human is a prototype of receptor type protein tyrosine phosphatases, which was cloned from human placental genome library using a phosphatase domain of CD45, a receptor type protein tyrosine phosphatase, as a probe (Streuli M. *et al.*, *J. Exp. Med.*, **168**, 1553-1562, 1988). CD45 is specifically expressed on hemocytic cells, whilst LAR is expressed on the cells other than hemocytic cells, particularly in insulin sensitive organs such as liver and skeletal muscle (Goldstein B. J., *Receptor*, **3**, 1-15, 1993). LAR is especially interesting among many types of receptor type PTPs due to its similarity of the extracellular domain to cell adhesion molecules. The entire structure of LAR is elucidated as having 150 kDa of extracellular E-subunit that consists of Ig-like domains and fibronectin type III domains, and 85 kDa of P-subunit (phosphatase subunit, set out in SEQ ID NO:1) comprising a transmembrane region and an intracellular domain having two phosphatase domains, which are covalently bound immediately outside of the cell membrane (see, Fig. 1, Streuli M. *et al.*, *EMBO J.*, **11**, 897-907, 1992). Additionally, LAR constitutes a subfamily together with PTP δ and PTP ϵ , and exists in peripheral portions of desmosomes (junctions with extracellular matrix through integrin) and in adherens junctions (intercellular adherent portions through cadherin), (Serra-Pages, C. *et al.*, *EMBO J.*, **14**, 2827-2838, 1995; Pulido, R. *et al.*, *Proc. Natl. Acad. Sci. USA*, **92**,

11686-11690, 1995; Kypta, R. M. *et al.*, *J. Cell Biol.*, **134**, 1519-1530, 1996; and Aicher, B. *et al.*, *J. Cell Biol.*, **138**, 681-696, 1997).

[0013] A large number of functional roles of LAR have been reported to date. For example, it was reported that responses to neurotrophin are decreased in LAR deficient nerves (Yang, T. *et al.*, 27th Annual Meeting of the Society for Neuroscience, New Orleans, Louisiana, USA, October 25-30, 1997, *Society for Neuroscience Abstracts*, **23**, 1-2, 1997); LAR homologues of *Drosophila* are predominantly expressed in nervous system, and the deficiency thereof results in delay of timely segregation of motor axon from nerve fascicle (Krueger, N. X. *et al.*, *Cell*, **84**, 611-622, 1996); poor development of mammary gland is observed upon disruption of the gene encoding a LAR enzyme domain (Schaapveld, R. Q. *et al.*, *Dev. Biol.*, **188**, 134-146, 1997); secretion of apolipoprotein B is decreased by suppression of the LAR activity (Phung, T. L. *et al.*, *Biochemical and Biophysical Research Communications*, **237** (2), 367-371, 1997); and loss of expression of LAR diminishes the size of cholinergic nerve cells of prosencephalon basement, thus control by the cholinergic nerve cells at hippocampal dentate gyrus is deteriorated (Yeo, T. T. *et al.*, *J. Neurosci. Res.*, **47**(3), 348-360, 1997). In such a manner, it has been gradually revealed that LAR is bearing several important roles in a living body. Furthermore at present, the most remarkable researches are directed to the relationships between LAR and insulin receptors (Hashimoto, N. *et al.*, *J. Biol. Chem.*, **267** (20), 13811-13814, 1992).

[0014] In 1995, a literature was presented which should be noted, reporting that the LAR tyrosine phosphatase activity is abnormally increased in adipose tissue of an obese person, with such an increase being suggested as a cause of onset of insulin resistance and a risk factor of cardiovascular diseases (Ahmad, F. *et al.*, *J. Clin. Invest.*, **95**(6) 2806-2812, 1995). Several reports followed thereafter illustrating that LAR is closely concerned with insulin receptors (Mooney, R. A. *et al.*, *Biochemical and Biophysical Research Communications*, **235** (3), 709-712, 1997; Orr, S. R. *et al.*, *Biochemical Society Transaction*, **25** (3), 452S, 1997; Ahmad, F. *et al.*, *J. Clin. Investigation*, **100** (2), 449-458, 1997; Ahmad, F. *et al.*, *J. Biol. Chem.*, **272** (1), 448-457, 1997; Norris, K. *et al.*, *Febs Letters*, **415**(3), 243-248, 1997; and Li, P. M. *et al.*, *Cellular Signaling*, **8** (7), 467-473, 1996). Further, on the basis of such information, Ahmad, F. *et al.* recently reported that PTP1B may be a therapeutic target of disease states involving in insulin resistance (Ahmad, F. *et al.*, *Metabolism. Clinical and Experimental*, **46** (10), 1140-1145, 1997).

[0015] Next, CD45 among the PTPs, which is also called as leukocyte common antigen (LCA), is a cell surface antigen that is expressed on all hemocytes (leukocytes) other than mature erythrocytes and platelets, and precursor cells thereof. CD45 is a receptor type PTP of which molecular weight ranging between 180 and 220 kDa, having two enzymatic regions intracellularly, and 8 to 9 kinds of isoforms exist which may result from alternative splicing of 3 to 4 exons proximate to N-terminal end of an extracellular region (Saga, Y. *et al.*, *Proc. Natl. Acad. Sci. USA*, **84**, 5364-5368, 1987; Thomas, M. L. *et al.*, *Proc. Natl. Acad. Sci. USA*, **84**, 5360-5363, 1987; and Trowbridge, I. S. *et al.*, *Annu. Rev. Immunol.*, **12**, 85-116, 1994). The amino acid sequences encoded by these exons that may be spliced are rich in serine, threonine and proline, and hardly forms the integrated three-dimensional structures based on α -helix, β -structures and the like, in addition, many O-glycosylated sites are included therein (Barclay, A. N. *et al.*, *EMBO J.*, **6**, 1259-1267, 1987). Therefore, CD45 may be characterized in that the structure of extracellular region can be greatly changed due to changes in the isoforms. Additionally, CD45 is highly expressed in lymphocytes, and intrinsic isomers may be expressed reversibly depending upon cell species, or states of activation of the cells (Thomas, M. L. *et al.*, *Annu. Rev. Immunol.*, **7**, 339-369, 1989; Charbonneau, H. *et al.*, *Annu. Rev. Cell Biol.*, **8**, 402-493, 1992; and Trowbridge, I. S. *et al.*, *Annu. Rev. Immunol.*, **12**, 85-116, 1994). Furthermore, the sequence of a region, which is interposed between the alternative structures and a transmembrane region, comprises a lot of cysteine, and forms a stabilized structure through disulfide bonds (Thomas, M. L. *et al.*, *Cell*, **41**, 83-93, 1985; Trowbridge, I. S. *et al.*, *J. Biol. Chem.*, **266**, 23517-23520, 1991; Trowbridge, I. S. *et al.*, *Biochim. Biophys. Acta*, **1095**, 46-56, 1991).

[0016] It is known that immunogen-specific responsiveness that was intrinsically possessed in the cells is remarkably lowered in variant T cell line with CD45 expression being lost, thus it is suggested that CD45 may be extremely important in activation of T cell via T cell receptors (TCR), and in functional expression thereof (Charbonneau, H. *et al.*, *Annu. Rev. Immunol.*, **7**, 339-369, 1989; Pingel, J. T. *et al.*, *Cell*, **58**, 1055-1065, 1989; Trowbridge, I. *et al.*, *Annu. Rev. Immunol.*, **12**, 85-116, 1994; Koretzky, G. A. *et al.*, *Nature*, **346**, 66-68, 1990; Koretzky, G. A. *et al.*, *Proc. Natl. Acad. Sci. USA*, **88**, 2037-2041, 1991; and Weaver, C. T. *et al.*, *Mol. Cell Biol.*, **11**, 4415-4422, 1991). In addition, it is also suggested that CD45 may participate in activation of Lck (p56^{lck}) and Fyn (p56^{lyn}), which are tyrosine kinases (PTK) in Src family and are binding to intracellular domain of CD4 and CD8 that are co-receptors of CD45 (Trowbridge, I. S. *et al.*, *Annu. Rev. Immunol.*, **12**, 85-116, 1994; and Penninger, J. M. *et al.*, *Immunol. Rev.*, **135**, 183-214, 1993). CD45 dephosphorylates tyrosine residues at a negative regulatory site located in C-terminal end of Lck or Fyn, and consequently, it is believed that Lck or Fyn is autophosphorylated to yield its active form, thus resulting in signal transduction (Penninger, J. M. *et al.*, *Immunol. Rev.*, **135**, 183-214, 1993; Ledbetter, J. A. *et al.*, *Curr. Opin. Immunol.*, **5**, 334-340, 1993; Janeway, C. A. Jr., *Annu. Rev. Immunol.*, **10**, 645-674, 1992; Cahir, McFarland, E. D. *et al.*, *Proc. Natl. Acad. Sci. USA*, **90**, 1402-1406, 1993; Hurley, T. R. *et al.*, *Mol. Cell Biol.*, **13**, 1651-1656, 1993; Sieh, M. *et al.*, *EMBO J.*, **12**, 315-321, 1993; Weiss, A. *et al.*, *Cell*, **76**, 263-274, 1994; and Chan, A. C. *et al.*, *Annu. Rev. Immunol.*, **12**, 555-592, 1994). From the experiments using CD45-deficient cell strain among insulin responsive myeloma cells, it was reported that

autophosphorylation of insulin receptors, tyrosine phosphorylation of IRS-1, and activation of PI3 kinase and activation of MAP kinase upon insulin stimulation were all enhanced to three fold in comparison with the strain expressing CD45 (Kulas, D. T. *et al.*, *J. Biol. Chem.*, **271**, 755-760, 1996), therefore, CD45 is supposed to be a negative regulatory factor of insulin similarly to LAR. Moreover, responsiveness of CD45-deficient cells was demonstrated to be recovered upon expression of molecules having only an intracellular region of CD45 by the following experiments. Namely, it was elucidated that: an enzymatic activity of tyrosine phosphatase can be sufficiently observed even when only the intracellular region of CD45 was expressed in bacterial or baculoviral systems (Ostergaard, H. L. *et al.*, *Proc. Natl. Acad. Sci. USA*, **86**, 8959-8963, 1989; Streuli, M. *et al.*, *Proc. Natl. Acad. Sci. USA*, **86**, 8698-8702, 1989); and signaling mediated by antigen receptors can be recovered by simply transfecting an intracellular region of CD45 to a T cell clone that is negative in CD45 (Volarevic, S. *et al.*, *Science*, **260**, 541-544, 1993; Hovis, R. R. *et al.*, *Science*, **260**, 544-546, 1993; and Desai, D. M. *et al.*, *Cell*, **73**, 541-554, 1993).

[0017] Besides, also in cases of B cell, it was indicated that not only early stage of signal transduction, but also ultimate proliferation, or the processes leading to apoptosis may be regulated through CD45 expression, according to the experiments using plasma cell species without expressing CD45 (Justement, L. B. *et al.*, *Science*, **252**, 1839-1842, 1991), or the experiments using CD45-negative clone that was established from immature B cell strain (Ogimoto, M. *et al.*, *Int. Immunol.*, **6**, 647-654, 1994). These results suggest that CD45 is a molecule that is bearing essential roles in antigen receptors- mediated signal transduction.

[0018] Accordingly, from the researches to date on PTPs such as LAR, CD45 and the like, it has been elucidated that PTPs bear extremely important roles in an intracellular signaling system, in conjunction with PTKs.

[0019] In 1992, Streuli *et al.* reported that binding between LAR E-subunit and P-subunit may be dissociated due to the noncovalency of their binding, and thus E-subunit is specifically shed from the cell membrane surface (Streuli, M. *et al.*, *EMBO J.*, **11** (3), 897-907, 1992). However, because many researchers have focused the studies using polyclonal or monoclonal antibodies elicited against a LAR E-subunit that is an extracellular domain thereof, a P-subunit even solely having phosphatase activities has been ignored. For example, when an anti-LAR antibody is used intending measurement of activity of LAR phosphatase, total phosphatase activity cannot be measured unless an antibody to the P-subunit is employed. Further, there exist several isoforms in extracellular domains of LAR family resulting from different types of mRNA splicing (Krueger, N. X. *et al.*, *Cell*, **84**, 611-622, 1996; Mizuno, K. *et al.*, *Mol. Cell Biol.*, **13**, 5513-5523, 1993; and Ogata, M. *et al.*, *J. Immunol.*, **153**, 4478-4487, 1994), thus different specificity to each isoform may be achieved when an antibody to an extracellular domain is used. In view of such circumstances, the present inventors started to produce antibodies to intracellular domains of PTPs.

[0020] Meanwhile, anti-CD45 antibodies were conventionally discriminated to antibodies that exhibit specificity to any of the CD45 isoforms having different molecular weights such as T200 or B220, and the antibodies that exhibit specificity only to a particular and restricted isoform, where the latter antibodies have been designated as CD45R (restricted) antibody (McMichael, A. J., In *Leucocyte Typing III*. Oxford University Press, Oxford, 1987). However, as diversities of structure of the extracellular domain of CD45 have been clarified, needs for classification of the specificity of the CD45R antibodies have been raised. Streuli *et al.* classified known human CD45 antibodies by a method using cDNA transfectants, and proposed to refer to the antibody that recognizes the structure that depends on alternative exon 4, 5, or 6 as CD45RA, CD45RB or CD45RC respectively (Streuli, M. *et al.*, *J. Immunol.*, **141**, 3910-3914, 1988). Using a similar method, Johnson *et al.* also reported classification of mouse CD45 antibodies (Johnson, P. *et al.*, *J. Exp. Med.*, **169**, 1179-1184, 1989).

[0021] For further references, known antibodies to PTPs may include an antibody that was generated using 196 amino acid residues as an antigen spanning from the transmembrane (TM) region of CD45 to a part of phosphatase domain 1 (Transduction Laboratories), and an antibody to phosphatase domain 1 (260 amino acid residues) of PTP α (Transduction Laboratories). However, it is unclear how these antibodies are immunospecific to phosphatase domains of LAR, and the other PTPs.

SUMMARY OF THE INVENTION

[0022] One aspect of the present invention is to provide an antibody having specificity to intracellular domains of two or more kinds of PTPs, and in particular, an antibody having specificity to an intracellular domain of at least one or more receptor type PTP. Particularly, the antibody according to the present invention may be an antibody having specificity to intracellular domains of LAR and/or CD45, preferably both of the intracellular domains of LAR and CD45. The antibody may preferably have specificity to phosphatase domains of PTPs.

[0023] The above-described antibody may be preferably generated using a polypeptide corresponding to a P-subunit of LAR that is encoded by a nucleotide sequence set out in SEQ ID NO: 1 or any of fragments thereof as an antigen. Further, preferred antibody may be a monoclonal antibody because of its immunospecific property.

[0024] In addition, the antibody may be generated using a fusion protein comprising a protein tyrosine phosphatase domain and another protein or a polypeptide, as an immunogen. The protein tyrosine phosphatase domain that is a

member of the fusion protein may preferably be a phosphatase domain of LAR, and as the another protein or the polypeptide, GST (glutathione-S-transferase) may be particularly suitable, besides, polyhistidine (preferably 6 histidine residues), calmodulin binding peptide (CBP), protein A and the like may be employed as the another protein or the polypeptide.

- 5 [0025] When polyhistidine is employed, absorption to nickel-chelating resin can be utilized for isolation and purification of the fusion protein expressed by a gene recombinant process, wherein addition of EDTA or imidazole substance as well as pH change may be adopted for dissociating the protein from the resin. When CBP is employed, the expressed fusion protein may be subjected to an affinity chromatography using calmodulin affinity resin, and then may be dissociated from the resin by adding EGTA. In addition, when protein A is employed, the expressed Fusion protein
10 may be subjected to an affinity chromatography using IgG sepharose (e.g., IgG Sepharose 6FF), and then may be dissociated from the resin by changing pH.

- [0026] Moreover, another candidate for the protein or the polypeptide fragment to be employed in the fusion protein may include for example, Xpress, Thioredoxin, c-myc, V5, HA/c-myc and the like. For isolation and purification of the intended fusion protein with a LAR phosphatase domain, expression of the protein may be followed by subjecting to an
15 antigen-antibody affinity column.

- [0027] The aforementioned preferable immunogen of the present invention, namely a fusion protein of GST and a LAR phosphatase domain, may be suitably produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours, preferably at 23-25°C for 18 hours; and then isolating the fusion protein from the culture
20 fluid and/or bacterial cells. Thus obtained fusion protein may be further purified based on an affinity to a support carrying glutathione, e.g., glutathione sepharose beads, wherein the elution of the fusion protein from the glutathione sepharose beads may be performed by boiling in the presence of a detergent. The detergent may include sodium dodecyl sulfate, CHAPS (3-[(3-cholamide propyl) dimethylammonio]-1-puopane sulfonate), deoxycholic acid, digitonin, n-dodecylmaltoside (1-O-n-dodecyl-β-D-glucopyranosyl (1-4) α-D-glucopyranoside), Nonidet™ P40 (ethylphenolpoly
25 (ethylene glycol ether)n), n-octylglucoside (1-O-n-octyl-β-D-glucopyranoside), sucrose monolaurate, Tesit™ (dodecylpoly (ethylene glycol ether)n), Triton™ X-100 (octylphenolpoly (ethylene glycol ether)n), Tween™ 20 (poly (oxyethylene) n-sorbitan-monolaurate), N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and the like [any of 'n' represents an integer number which is more than or equal to 1]. When elution of the fusion protein is carried out, the resin may be boiled at 100°C for 5-10 minutes in the presence of such detergents at a concentration that does not lead any problems
30 to an animal to be administered, preferably in the presence 0.1% of sodium dodecylsulfate. Accordingly, a purified fusion protein, which is preferable as a contemplated immunogen, can be obtained.

- [0028] When a monoclonal antibody is generated using such a fusion protein as an immunogen, a protein tyrosine phosphatase domain, preferably a LAR phosphatase domain may be employed for screening the antibody, however, it is more preferable to perform the screening using the fusion protein as an immunogen in terms of the specificity.

- 35 [0029] The monoclonal antibody of the present invention may include a monoclonal antibody that is produced from mouse/mouse hybridoma cells, and has specificity to intracellular domains of phosphatase subunits of LAR and CD45. For example, such an antibody of the present invention may include a monoclonal antibody having an apparent molecular weight of about 146 kDa on SDS-PAGE. The antibody can be applied as a tool for further elucidation of the mechanisms of an insulin signaling system, for developing useful diagnostic methods of insulin resistance and NIDDM, and
40 for prophylaxis, therapeutics and diagnosis of several kinds of pathological states relating to syndrome X based on insulin resistance.

- [0030] Further aspect of the present invention is to provide a hybridoma cell line producing the above-mentioned monoclonal antibody. Such a hybridoma cell line may include mouse/mouse hybridoma cell line YU2, which was deposited on May 7, 1998, with National Institute of Bioscience and Human-Technology, Agency of Industrial Science
45 and Technology, 1-1-320, Higashi, Tsukuba, Ibaraki, JAPAN, and assigned Accession No. FERM BP-6344.

- [0031] The antibody of the present invention has specific immunoreactivity with PTP protein, and fragments and polypeptides that comprise at least a part (more than or equal to three amino acid residues, preferably, more than or equal to five amino acid residues) of an intracellular domain of PTP (the fragment and polypeptide are hereinafter collectively referred to as 'PTP derived molecules'), which was derived from natural sources, or wholly or partially synthesized (such as those chemically synthesized, or recombinantly synthesized).
50

- [0032] Another aspect of the present invention is to provide a method for generating an antibody having specificity to two or more kinds of protein tyrosine phosphatase subunits, wherein the aforementioned fusion protein comprising a protein tyrosine phosphatase domain and another protein or a polypeptide fragment, preferably a GST-LAR phosphatase domain fusion protein, is employed as an immunogen. In this aspect of the present invention, the available
55 another protein or a polypeptide fragment except GST to be a member of the fusion protein, and purification process of the fusion protein are as set forth above.

- [0033] Further, a fusion protein comprising GST and a LAR phosphatase domain which is a preferable immunogen may be suitably produced by: culturing *Escherichia coli* transformed or transfected with an expression vector compris-

ing a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours, preferably at 23-25°C for 18 hours; and then isolating the fusion protein from the culture fluid and/or bacterial cells. Thus obtained fusion protein may also be further purified based on an affinity to a support carrying glutathione, eg., glutathione sepharose beads, wherein the elution of the fusion protein from the glutathione sepharose beads may be performed by boiling in the presence of a detergent, as set forth above, and again, for eluting the fusion protein, the resin may be boiled at 100°C for 5-10 minutes in the presence of the detergent at a concentration which does not lead any problems to an animal to be administered, preferably in the presence of 0.1% of sodium dodecylsulfate. Accordingly, the purified fusion protein, which is preferable as a contemplated immunogen, can be obtained.

[0034] In a method of generating a monoclonal antibody by using such a fusion protein as an immunogen, a protein tyrosine phosphatase domain, preferably a LAR phosphatase domain may be employed for screening the antibody, however, it is more preferable to perform the screening using the fusion protein that was employed as an immunogen in terms of the specificity.

[0035] Furthermore, the present invention provides a method of isolating a novel PTP comprising a step for screening PTP, wherein the aforementioned antibody is used in the step of screening. It is contemplated that expression screening of a cDNA library may be performed in the screening step.

[0036] In yet another aspect of the present invention, a method of quantitative determination of PTP and/or PTP derived molecules is provided. In this method, an amount of PTP protein and/or a fragment or a polypeptide that comprises at least a part of a PTP intracellular domain, which is contained in a test sample, is determined using the antibody set forth above. The antibody set forth above is used preferably in any of immunoblotting, immunoprecipitation and ELISA, for determination in this method.

[0037] Still another aspect of the present invention is to provide a method for quantitative determination of PTP protein and/or PTP derived molecules comprising the steps of: isolating PTP and/or a fragment or a polypeptide that comprises at least a PTP intracellular domain from a test sample using the antibody set forth above; and measuring an activity of the isolated PTP and/or PTP derived molecules. In this step for isolation, affinity chromatography and/or immunoprecipitation by using a support that was bound with the aforementioned antibody may be suitably utilized.

[0038] In yet another aspect of the present invention, a method for producing PTP and/or PTP derived molecules is provided, comprising the step of isolating PTP protein and/or a fragment or a polypeptide that comprises at least a PTP intracellular domain using the antibody set forth above. In this step for isolation, affinity chromatography and/or immunoprecipitation by using a support that was previously bound with the antibody described above may be suitably utilized.

[0039] Further aspect contemplated by the present invention is to provide a method for identifying the presence of PTP and/or PTP derived molecules within tissue comprising the step of performing immunohistological examination using the aforementioned antibody. As the immunohistological examination, the technique such as *in situ* immunohistological staining with a labelled antibody may be adopted, thus PTP protein and/or a fragment or a polypeptide that comprises at least a PTP intracellular domain, can be detected.

[0040] Besides, the present inventors found that a monoclonal antibody having specific immunoreactivity with LAR can specifically recognize thyroid carcinoma cells. Therefore, the above-mentioned antibody of the present invention is presumed to be useful in diagnosis, therapy and the like of thyroid cancer.

BRIEF DESCRIPTION OF THE DRAWING

[0041]

Figure 1 is a schematic drawing depicting a subunit structure of LAR (a); and a schematic drawing illustrating the mutated LAR phosphatase domain structures inside the membrane (b) prepared as demonstrated in Experimental Examples.

Figure 2 represents immunoblots illustrating time dependent tyrosine phosphorylation induced by insulin stimulation in COS cells that were cotransfected with LAR/CS and wild type insulin receptor (IR).

Figure 3 represents immunoblots illustrating phosphorylation-dephosphorylation in COS cells that were cotransfected with wild type or mutants of LAR, and wild type insulin receptor.

Figure 4 represents an immunoblot illustrating dephosphorylation of a β -chain of insulin receptor by wild type or mutants of LAR.

Figure 5 represents an immunoblot illustrating tyrosine phosphorylation in COS cells that were cotransfected with wild type or mutant of insulin receptor, and LAR/CS.

Figure 6 represents SDS-polyacrylamide gel, showing a molecular weight of the antibody YU2 of the present invention.

Figure 7 represents immunoblots showing immunospecificity of the antibody YU2 of the present invention.

Figure 8 represents analytical results of immunoblotting on CD45 using the antibody YU2 of the present invention

Figure 9 represents homology of amino acid sequences of intracellular domains of LAR and CD45.

Figure 10 is a schematic drawing depicting a signal transduction cascade of insulin that is controlled by phosphorylation-dephosphorylation in which insulin receptor and LAR participate.

5 BEST EMBODIMENT FOR CARRYING OUT THE INVENTION

Experimental Example 1: Tyrosine phosphorylation of insulin receptors by LAR mutants and studies on association between LAR and insulin receptors

10 [0042] First, in order to elucidate the mechanisms controlling signal transduction of insulin by LAR, analysis was performed with a strategy in which mutated LAR is used that was prepared by substitution of cysteine with serine, which exists in a catalytic center of PTP domain of LAR.

A) Expression vector of LAR and insulin receptors

15 [0043] Three kinds of LAR expression vectors were used, i.e., (a) LAR WT: human wild type LAR (SEQ ID NO: 3); (b) LAR C/S: mutated LAR, having substitution of cysteine in a catalytic center of LAR-PTP domain 1 (amino acid residue position 1552 of SEQ ID NO: 3) for serine by substituting nucleotide G, position 4983 of SEQ ID NO: 3, with C; and (c) LAR DC/S: further mutated one in addition to LAR C/S, with substitution of cysteine in LAR-PTP domain 2 (amino acid residue position 1813 of SEQ ID NO: 3) for serine by substituting nucleotide G, position 5856 of SEQ ID NO: 3, with C (see, Fig. 1 (b)), each of which was incorporated into pMT expression vector (see, Streuli M. *et al.*, *EMBO J.*, **11**, 897-907, 1992; and Streuli M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990).

20 [0044] Meanwhile, the employed insulin receptor expression vectors were: (a) IR WT: wild type; and (b) IR K1018M: mutated insulin receptor having substitution of lysine, position 1018 of ATP binding site of wild type insulin receptor, with methionine resulting in deficiency of tyrosine kinase activity, each of which cDNA was incorporated to downstream of SR α promoter (see, Kanai F. *et al.*, *Biochemical and Biophysical Research Communications*, **195**, 762-768, 1993).

B) Transfection into COS-7 cells

30 [0045] COS-7 cells were seeded into RPMI 1640 medium (Nissui Pharmaceutical Co., LTD.) supplemented with 10% fetal calf serum at 1.0×10^5 cells/8 mL/90 ϕ dish, then after 16 hours incubation, expression vectors of LAR C/S and IR WT were cotransfected into COS-7 cells using DEAE-dextran method. The LAR C/S employed was a vector that was revealed to include complete deficiency in tyrosine phosphatase activities *in vitro* (Streuli M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990) according to mutation as mentioned above in paragraph A, (b).

35 [0046] Cotransfection was performed according to the following procedure. Initially, 40 μ l of 10 mM chloroquine was added to 4 ml of RPMI 1640 medium (10.2 g/L of RPMI 1640 (Nissui Pharmaceutical Co., LTD.) containing 0.3 g of glutamine and 0.1 g of kanamycin, pH 7.4 that was adjusted with 10% NaHCO₃) containing 2% FCS. To 2 ml of this solution, 5 μ g of LAR expression vector and 1 μ g of IR expression vector were added, on the other hand, 16 μ l of 100 mg/ml DEAE-dextran was added to the remaining 2 ml of the solution. Then, both solutions were mixed thoroughly with 40 stirring. Thus prepared solution of expression vector, 3.75 ml was plated at 1.0×10^6 cells/8 ml/dish, and was added to COS-7 cells that had been precultured for 16 hours at 37°C, in a 5% CO₂ incubator. Following 4 hours culture under the similar conditions to the preculture, the cells were treated with 10% DMSO solution for 2 minutes, then washed with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄ · 12H₂O, 1.4 mM KH₂PO₄), thereafter, 8 ml of RPMI1640 containing 10% FCS was added thereto, and cultured for 48 hours at 37°C in an incubator that was adjusted to 5% CO₂.

C) Insulin stimulation and preparation of cell lysate

45 [0047] COS-7 cells after completing the transfection were incubated for 16 hours in serum free RPMI 1640 culture medium, followed by stimulation with 10^{-7} M insulin (Seikagaku Corporation) for determined periods, i.e., 0, 1, 5, 15 and 30 minutes. Stimulation for 0 minute was conducted by standing on ice without incubating at 37°C, although insulin was added similarly. After each of the time elapsed from the beginning of insulin stimulation, culture fluid was entirely aspirated therefrom, and 5 ml of PBS w/lnh. (PBS containing tyrosine phosphatase inhibitors: 1 mM sodium vanadate, 5 mM sodium fluoride, 5 mM sodium pyrophosphate, 5 mM EDTA-2Na, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄ · 12H₂O, 1.4 mM KH₂PO₄) was immediately added.

50 [0048] Following washes of the whole cells with PBS w/lnh., the fluid was removed by aspiration, and 1 ml of lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM iodoacetamide, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.4 mM sodium vanadate, 0.1 mM oxidized phenylarsine, 1 mM benzamide, 1 mM phenylmethylsulfonyl fluoride) was added to the cells, which were thereafter collected with a cell scraper. The cell

suspension was transferred to a 1.5 ml tube, and then incubated at 4°C for 30 minutes to effect complete lysis of the cells. Supernatant, which was obtained by centrifuge of the fluid at 12,000 rpm, 4°C for 10 minutes following incubation was employed as a cell lysate in the experiments set forth below.

5 D) Immunoprecipitation

[0049] Immunoprecipitation was performed for the cell lysate obtained as above paragraph C, with an anti-LAR E-subunit antibody (a mixture of 7.5 µg of 11.1A and 7.5 µg of 75.3A, see, Streuli M. *et al.*, *EMBO J.*, 11, 897-907, 1992). To 1 ml of the above cell lysis solution, 15 µg of MOPC 21 (mouse IgG1κ; Sigma Corporation) as a mock was added, then the solution was incubated at 4°C for one hour, added with 20 µl γ-bind (GammaBind Plus Sepharose: Pharmacia Biotech Inc.) thereto, and further incubated for one hour at 4°C to execute preabsorption. The solution was centrifuged at 4°C, 12,000 rpm for 10 minutes, then 950 µl of the supernatant was transferred to another tube. Next, 15 µg of anti-LAR E-subunit antibody was added to the supernatant, then the solution was incubated at 4°C for one hour, added with 20 µl of γ-bind thereto, and further incubated for one hour at 4°C. After centrifuge at 4°C, 12,000 rpm for 10 minutes, the precipitate was washed with 1 ml of lysis buffer twice, then once with PBS w/Inh., and suspended in 20 µl of SDS sample buffer. The suspension was heated for 5 minutes in a boiling water bath to prepare a sample for electrophoresis.

E) Immunoblotting

[0050] The above-mentioned sample was subjected to electrophoresis using 7.5% SDS-polyacrylamide gel, followed by transfer to a nitrocellulose membrane (Schleicher & Schuell) using a transfer device at 400 mA for 4 hours. Then blocking was conducted by incubating the membrane in 3% bovine serum albumin solution for longer than 30 minutes at a room temperature. After washing with sufficient volume of TBS-T (TBS with Tween 20: 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween 20) for 10 minutes more than twice, an anti-phosphotyrosine antibody (4G10, UBI) that was 50,000-fold diluted with TBS-T, the anti-LAR E-subunit antibody or an anti-insulin receptor β-chain antibody (UBI) was added thereto, then the mixture was shaken for one hour at a room temperature. After washing with sufficient volume of TBS-T for 5 minutes more than three times, 15 ml of TBS-T solution containing HRP-labelled anti-mouse IgG antibody (horseradish peroxidase-labelled anti-mouse IgG: Santa Cruz Biotechnology, Inc.) 1.5 ml was added thereto, and shaken for one hour at a room temperature. After washing with sufficient volume of TBS-T for 5 minutes more than three times, bands of the protein were detected that can bind to each of the antibodies, by means of a chemiluminescence method using a kit of luminescence reagents (Wako Pure Chemical Industries, Ltd.).

F) Results

[0051] As results of immunoblotting with the anti-phosphotyrosine antibody following to immunoprecipitation with the anti-LAR E-subunit antibody of cell lysate prepared after stimulation with insulin for determined time periods of cotransfected COS-7 cells with LAR C/S and IR WT in the above-described manner, tyrosine phosphorylation of an insulin receptor β-chain as well as a 85 kDa protein could be observed with the insulin stimulation for 1 minute. Such tyrosine phosphorylation could also be successively observed with the insulin stimulation for 30 minutes (see, Fig. 2A). [0052] Furthermore, results from the immunoblotting with the anti-LAR E-subunit antibody (Fig. 2B), the anti-insulin receptor β-chain antibody (Fig. 2C) and the anti-phosphotyrosine antibody (Fig. 2A) demonstrated that LAR and insulin receptor may associate depending on the presence or absence of tyrosine phosphorylation of the insulin receptor.

Experimental Example 2: Studies on tyrosine dephosphorylation of insulin receptor by various LAR (1)

[0053] Next, COS-7 cells were similarly cotransfected with LAR WT, LAR C/S or LAR DC/S, and IR WT followed by stimulation with insulin for 5 minutes, and immunoprecipitation with the anti-LAR E-subunit antibody, and then immunoblotting with various types of antibodies for the precipitates was carried out. Consequently, tyrosine phosphorylation of the insulin receptor β-chain or the 85 kDa protein could not be detected for the cells cotransfected with insulin receptor and LAR WT, in comparison with the cells cotransfected with LAR C/S or LAR DC/S (see, Fig. 3A).

[0054] Additionally in these experiments, amounts of expression of LAR (Fig. 3C) and the insulin receptor (Fig. 3D) were almost identical in both of the cotransfectants, therefore LAR WT was suggested to dephosphorylate the phosphorylated tyrosine of the insulin receptor β-chain as well as the 85 kDa protein.

[0055] Further, when the immunoprecipitates with the anti-LAR E-subunit antibody were immunoblotted using the anti-insulin receptor β-chain antibody, the cotransfectant with LAR DC/S showed a weaker band of an insulin receptor β-chain, compared to the cotransfectant with LAR WT or LAR C/S (Fig. 3B).

[0056] These results indicate that the association between insulin receptor and LAR DC/S is weaker, when compared with that of LAR WT or LAR C/S. The only one difference between LAR C/S and LAR DC/S is one amino acid

residue position 1813 of phosphatase domain 2, accordingly, this domain 2, which was postulated to involve in binding with substrates without tyrosine phosphatase activity, was proved to be playing a role in binding between LAR and insulin receptor.

5 Experimental Example 3: Studies on tyrosine dephosphorylation of insulin receptor by various LAR (2)

[0057] In order to further study as to whether tyrosine dephosphorylation of insulin receptor occurs only in cases where LAR was bound, or in every insulin receptor, cell lysate of the cotransfectant was subjected to electrophoresis, and then immunoblotted with the anti-phosphotyrosine antibody. Consequently, tyrosine dephosphorylation of insulin
10 receptor was markedly found only in cells that had been cotransfected with LAR WT (see, Fig. 4).

Experimental Example 4: Studies on tyrosine phosphorylation of insulin receptor in the presence of LAR C/S

[0058] In order to elucidate whether tyrosine phosphorylation of the 85 kDa protein is effected by a tyrosine kinase activity of insulin receptor, COS-7 cells were cotransfected with LAR C/S, and IR WT or IR K1018M (IR MT) having a deficiency in tyrosine kinase of insulin receptor. Following insulin stimulation of the cells for 5 minutes, immunoprecipitation was performed with the anti-LAR E-subunit antibody, and immunoblotting with the anti-phosphotyrosine antibody was carried out (see, Fig. 5). Consequently, the cells cotransfected with IR WT showed tyrosine phosphorylation of an insulin receptor β -chain and the 85 kDa protein upon stimulation with insulin, however, the cells cotransfected with IR
20 K1018M showed no such phosphorylation at all.

[0059] From these results, it was revealed that rapid tyrosine phosphorylation of insulin receptor β -chain occurs upon binding of insulin to insulin receptor; and that the insulin receptor tyrosine kinase leads tyrosine phosphorylation of the 85 kDa protein.

[0060] The 85 kDa protein was therefore speculated as a P-subunit of LAR of which binding to insulin receptor was demonstrated.
25

Example 1: Generation of anti-tyrosine phosphatase P-subunit antibodies

[0061] Anti-tyrosine phosphatase P-subunit antibodies were generated according to the following procedures.
30

A) Preparation of immunogen

[0062] Glutathione-S-transferase-LAR fusion protein (GST-LAR) was employed as an immunogen. *E. coli* AD202 was transformed with an expression vector, pGEX-2T vector (Pharmacia Biotech Inc.), which was incorporated to its *Bam*HI/*Eco*RI site with cDNA corresponding to 607 amino acids spanning from the end of a transmembrane region of a LAR P-subunit to the entire cytoplasmic region (SEQ ID NO: 1, 3467 bp) according to a general procedure. After the *E. coli* was incubated overnight in LB (Amp. +) agar medium (LB (Amp. +) described below containing 7.5 g of agar), single colony was inoculated to 50 ml of LB (Amp. +) medium (containing triptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, 5 N NaOH 0.2 mL/L, and ampicillin 50 μ g / ml), and further incubated overnight. Then the incubation mixture of *E. coli*
40 was inoculated to 500 ml of LB (Amp. +) medium, and incubated at 37°C until absorbance at 600 nm reaches to approximately 1.0, followed by addition of 50 μ l of 1 M IPTG (isopropyl- β -D(-)-thiogalactopyranoside, Wako Pure Chemical Industries, Ltd.) and an incubation at 25°C overnight. Thus resulted culture was centrifuged at 3,000 rpm, 4°C for 15 minutes, and the precipitated bacterial bodies were suspended in 50 ml of NETN (0.5 % Nonidet P-40, 1 mM EDTA, 20 mM Tris-HCl pH 8.0, 100 mM NaCl). Thereafter, the suspension was subjected to twice repeated treatments of ultrasonication for 1 minute and standing on ice for one minute, and then centrifuged at 14,000 rpm, 4°C for 20 minutes to obtain the supernatant. To 10 ml of the lysate of the *E. coli*, 100 μ l of suspension of glutathione sepharose beads (Glutathione Sepharose 4B (Pharmacia Biotech Inc.) that had been prepared by washing three times, and suspended in 50% NETN) was added, and then incubated for 30 minutes at a room temperature. Thus resulted suspension was centrifuged at 3,000 rpm, 4°C for 5 minutes, and supernatant was removed. The precipitated glutathione sepharose beads
50 were washed twice with NETN, then once with PBS, thereafter 100 μ l of SDS sample buffer (125 mM Tris-HCl pH 6.8, 0.1% sodium dodecylsulfate, 5% 2-mercaptoethanol) was added thereto, and heated in a boiling water bath for 10 minutes to elute the GST-LAR fusion protein. The eluate from which the beads were eliminated was concentrated by centrifuge using Centricon-10 (Amicon) at 3,000 rpm, 4°C for 45 minutes. One ml of PBS was added to the concentrate in order to bufferize the solution, and the solution was concentrated again by centrifuge at 3,000 rpm, 4°C for 45 minutes. This process for bufferization was repeated twice, and thus resulted solution was employed as an immunogen solution. Purification and concentration of the antigenic protein were confirmed by SDS-polyacrylamide gel electrophoresis.

[0063] Meanwhile, on a final immunization, the antigen solution was prepared in a different process because it should be administered intravenously. The lysate of the above-described *E. coli* that is expressing GST-LAR fusion pro-

tein was incubated with glutathione sepharose beads, and after centrifuge, the precipitated beads were washed twice with NETN, and three times with PBS. Next, 100 μ l of GSH elution buffer (20 mM glutathione, 1M Tris-HCl, pH 9.6) was added thereto, and the mixture was gently stirred for 10 minutes at a room temperature to accomplish the elution of GST-LAR. After repeating the steps of centrifuge at 3,000 rpm, 4°C for 5 minutes and recovering the supernatant three times in total, the total eluate was dialyzed in saline at 4°C for 2 days, then thus obtained solution was employed as an immunogen solution for intravenous administration.

B) Immunization

[0064] Eight female Balb/c mice of 6 weeks old received intraperitoneal administration of pristane (2,6,10,14-tetramethylpentadecane, Sigma Corporation) at 0.5 ml/animal. After 2 weeks passed, the antigen solution for intraperitoneal immunization that was emulsified by blending with Freund's complete adjuvant (Gibco Inc.) at a ratio of 1:1 was intraperitoneally administered at about 10 μ g of GST-LAR fusion protein per one mouse. Thereafter, the antigen solution for intraperitoneal immunization that was admixed with Freund's incomplete adjuvant (Gibco Inc.) at a ratio of 1:1 was prepared to be about 30-70 μ g of GST-LAR per one mouse, and the mixture was intraperitoneally administered four times approximately once every 2 weeks. On day 4 after the fourth immunization, blood was collected from ocular fundus vein, and an antibody titer in the serum was determined by ELISA method.

C) ELISA

[0065] Protein solutions of GST-LAR and GST alone that were prepared similarly to the procedure of preparation of the antigen for intravenous immunization were respectively dialyzed against purified water at 4°C overnight. These solutions were adjusted to 0.5 μ g/ml in PBS, and subjected to absorption to an ELISA plate (Falcon 3911 MicroTest™ Flexible Assay Plate) at 50 μ l/well for one hour. After five times washes with wash buffer (PBS containing 0.05% Tween20), blocking with 5% skim milk (prepared by dissolving 2.5 g of skim milk in 50 ml of PBS) was conducted. Following washes, the serum as obtained in the above section B was diluted to 16,000 fold with dilution buffer (PBS containing 0.25% BSA), and was added to the wells at 50 μ l/well, and then incubated for one hour in a wet box. After washing the plate, HRP-labelled anti-mouse IgG antibody that was diluted to 1,000 fold was added to the plate at 50 μ l/well, and incubated for one hour. Following washes with wash buffer four times and once with PBS, a substrate solution of o-phenylenediamine (Wako Pure Chemical Industries, Ltd.) that was dissolved in a citrate buffer (prepared by dissolving 5.6325 g of citric acid monohydrate and 18.35 g of Na₂HPO₄ · 12H₂O in purified water to make 500 ml in total) at a concentration of 1 mg/ml was added at 50 μ l/well, allowed for reaction for 30 minutes, and then 50 μ l of 10% H₂SO₄ was added to terminate the reaction. Fifty μ l of the solution was transferred to each well of a 96-well plate (Sumitomo Bakelite Co., LTD.) for measurement, and then absorbance at 450 nm was measured.

D) Cell fusion

[0066] Two mice that showed elevation of the antibody titer to GST-LAR in accordance with the results of the above ELISA were finally immunized by intravenous administration, and spleen was excised therefrom on the third day to prepare splenocytes according to an ordinary procedure.

[0067] Parent cells employed for cell fusion were Balb/c mouse-derived myeloma cell strain NS1 that was previously selected in a medium containing 20 μ g/ml 8-azaguanine, and confirmed as hypoxanthine, guanine, phosphoribosyl transferase (HGPRT) deficient strain. Cell fusion and cloning were performed with 2×10^7 of NS1 cells and 1×10^8 of splenocytes, using ClonaCell™ - HY Hybridoma Cloning Kit (StemCell Technologies Inc.).

[0068] Screening of the supernatant from the culture of the cloned hybridoma was carried out according to ELISA method described in section C above, with 50 μ l of the supernatant of hybridoma culture using plates that were bound with 0.5 μ g/ml protein solution of GST, GST-LAR or GST-CD45 (Furukawa, T. *et al.*, *Proc. Natl. Acad. Sci. USA*, **91**, 10928-10932, 1994) prepared by the similar method for preparation of the antigen for intravenous immunization as described above. In this ELISA method, hybridoma was selected, which did not show any immune response to the wells bound with GST, but showed an immune response to the wells bound with GST-LAR or GST-CD45. Passage culture of the cloned hybridoma was conducted in RPMI 1640 medium (Nissui Pharmaceutical Co., LTD.) containing 10% fetal bovine serum (Gibco Inc.).

[0069] Through screening by ELISA method of the culture supernatant in this manner from the hybridoma that was HAT selected, a clone YU2 having both stable antibody producibility and proliferation ability could be obtained.

[0070] This hybridoma cell line YU2 was deposited on May 7, 1998, with National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-1-320, Higashi, Tsukuba, Ibaraki, JAPAN, and assigned Accession No. FERM BP-6344.

E) Typing of monoclonal antibody

[0071] Supernatant of 0.5 ml from culture of hybridoma YU2 obtained in the above section D was diluted with 4.5 ml of TBS-T, and the isotype was determined for 3 ml of the diluted solution using mouse monoclonal antibody isotyping kit (Amersham International plc.). As a result, the isotype of the antibody was proved to be IgG1k.

F) Generation and purification of monoclonal antibody

[0072] Balb/c mice of 6 weeks old received intraperitoneal administration of pristane at 0.5 ml/animal, and after 10 days, hybridoma cell YU2 that was obtained by cloning in section D above was intraperitoneally injected at 2.5×10^6 - 1.3×10^7 cells/0.5 ml/animal. Abdominal hypertrophy was observed approximately 10 days thereafter, accordingly, ascites fluid was collected several times using a 20-gauge injection needle. Thus collected ascites fluid was centrifuged at 1,000 rpm, 4 °C for 5 minutes to separate supernatant and precipitate. The supernatant was incubated at 37 °C for 30 minutes, and allowed to stand at 4 °C overnight. Following centrifuge at 12,000 rpm, 4°C for 10 minutes, the monoclonal antibody YU2 was purified using an affinity column HiTrap ProteinG (Pharmacia Biotech Inc.) from the 1.5 ml of supernatant thus obtained. Absorbance at 280 nm of the antibody solution thus obtained was measured, and then concentration of the antibody was calculated using molecular extinction coefficient of mouse IgG.

[0073] In addition, a molecular weight of the monoclonal antibody YU2 was estimated from mobility on SDS-polyacrylamide gel electrophoresis. The results are shown in Fig. 6. As is clear from the Fig. 6, the monoclonal antibody YU2 comprises H-chain of about 48 kDa and L-chain of about 25 kDa, having a total molecular weight of about 146 kDa.

Example 2: Studies on specificity of monoclonal antibody (1)

[0074] An expression vector of LAR WT was transfected into COS-7 cells according to the procedures described in Example 1, sections A and B. Following immunoprecipitation of the cell lysate with the purified monoclonal antibody obtained in Example 1, immunoblotting was carried out. As a control on immunoprecipitation, MOPC 21 was employed because the anti-LAR E-subunit antibody (*supra*), an anti-CD45 antibody (Santa Cruz Biotechnology, Inc., 35-Z6), and the monoclonal antibody YU2 all belong to IgG1 subclass.

[0075] On the analyses using the LAR enforced expression system in COS-7 cells, the monoclonal antibody YU2 recognized the protein of 85 kDa that corresponds to a LAR P-subunit and the protein of about 200 kDa that corresponds to a precursor, following immunoprecipitation with the anti-LAR E-subunit antibody (see, Fig. 7B).

[0076] Moreover, upon immunoblotting with an antibody that recognizes a LAR E-subunit after immunoprecipitation of cell extract of COS-7 cells transfected with LAR using these antibodies (IgG1, IgG2b, or YU2), detection of the protein of 150 kDa that corresponds to a LAR E-subunit and the protein of about 200 kDa that corresponds to a precursor was restricted only to that immunoprecipitated with the antibody YU2 (see, Fig. 7A).

[0077] From the results set forth above, it was revealed that the monoclonal antibody YU2 could be utilized for immunoprecipitation and immunoblotting of a LAR P-subunit.

[0078] Meanwhile, YU2 exhibited the reactivity in ELISA using GST-CD45 (Furukawa, T. *et al.*, *Proc. Natl. Acad. Sci. USA*, **91**, 10928-10932, 1994) as an antigen, accordingly, it was speculated that YU2 recognized a common antigen of LAR and CD45 (presumably, a sequence in PTP domain that is conserved in both proteins) as an epitope.

Example 3: Studies on specificity of monoclonal antibody (2)

[0079] In order to further investigate specificity of the monoclonal antibody YU2, expression of CD45 in COS-7 cells was enforced according to the similar procedure described in Experimental Example 1, thereafter the cell extract was subjected to immunoblotting analysis using YU2, and the bands were identified at positions corresponding to about 200 kDa and about 180 kDa (see, Fig. 8).

[0080] These bands were also detected at the same positions when the blot was reprobbed using commercially available anti-CD45 antibody, accordingly, it was verified that these bands are derived from CD45.

[0081] From the results of the above Examples 2 and 3, it was demonstrated that YU2, which was picked up as a clone that exhibits reactivity with both of the intracellular domains of LAR and CD45 in screening of the hybridoma by means of ELISA method, can recognize CD45 also in immunoblotting.

[0082] Homology between amino acid sequences of intracellular domains of LAR and CD45 is shown in Fig. 9. In the figure, "*" denotes the identical amino acid, whereas "." denotes the similar amino acid between both amino acid sequences. When the amino acid sequences from the phosphatase domain 1 to C-terminal end in the intracellular domains of LAR and CD45 are compared, it was revealed that the homology was 39.4%. Among them, 12 amino acids corresponding to the vicinity of consensus sequence that carries tyrosine phosphatase activity in domain 1 (Val-Val-His-Cys-Ser-Ala-Gly-Val-Gly-Arg-Thr-Gly; SEQ ID NO: 4 (amino acids from position 245 to 256 in SEQ ID NO: 1) are com-

pletely identical (the portion depicted with outline characters in Fig. 9). It is reported that a polypeptide must include approximately 8 to 10 amino acids in order to be a possible antigen determinant, therefore, it is expected that YU2 may recognize the consensus sequence of the phosphatase comprising the 12 amino acids set out in SEQ ID NO: 4 as an epitope.

5 **[0083]** In Fig. 9, eight sites corresponding to the portions of consensus sequences in the intracellular domains of LAR and CD45 with other known PTPs (namely, PTP α , β , γ , δ , ϵ , σ , μ , κ , η , ζ and the like) are depicted with closed boxes. These consensus sequences in the eight sites are repetitive sequences of four kinds of sequences ((1) to (4) in Fig. 9) of which details are as follows:

- 10 (1) Phe-Trp-(Arg/Glu/Leu)-Met-(Val/Ile/Cys)-Trp (SEQ ID NO: 5)
 (2) Lys-Cys-(Ala/Asp)-(Gln/Glu/Lys)-Tyr-Trp-Pro (SEQ ID NO: 6)
 (3) Trp-Pro-Asp-(His/Phe)-Gly-Val (SEQ ID NO: 7)
 (4) Pro-Xaa-(Ile/Val)-(Ile/Val)-His-Cys-Xaa-Ala-Gly-Xaa-Gly-Arg-(Thr/Ser)-Gly (SEQ ID NO: 8)

15 **[0084]** The above-mentioned identical sequences of LAR and CD45 set out in SEQ ID NO: 4 are included in the consensus sequence (4) in domain 1. It is expected that the antibody of the present invention that can recognize such a consensus sequence of PTP as an epitope can be utilized advantageously in analysis and quantitative determination of PTPs, identification, detection, isolation and purification of novel PTPs.

20 **[0085]** In addition, as is shown in Figure 10, tyrosine kinase activity is increased upon autophosphorylation of the β -chain of insulin receptor when insulin is bound to the α -chain of the insulin receptor. Due to the activity of the tyrosine kinase, insulin actions such as glucose uptake, glucose metabolism, and cell proliferation may be finally achieved. The present inventors clarified that the activated insulin receptor may change back into the inactivated state through tyrosine dephosphorylation by LAR (see, International Application PCT/JP98/02542, filed on June 5, 1998). Moreover, the possibilities were suggested that: (1) insulin receptor tyrosine kinase may phosphorylate tyrosine in intracellular domain of
 25 LAR; (2) such phosphorylation may participate in determination of substrate specificity of LAR, or in increase of phosphatase activity; and (3) LAR may control its own enzymatic activity through autodephosphorylation of the phosphorylated tyrosine, accordingly, it was demonstrated at the molecular level that acceleration of the enzymatic activity of LAR may cause insulin resistance. According to the antibody of the present invention, elucidation of signal transduction mechanisms and various other control mechanisms in which phosphorylation and/or dephosphorylation may partici-
 30 pate can be achieved, where LAR and CD45 as well as other PTPs may be involved.

INDUSTRIAL APPLICABILITY

35 **[0086]** The antibodies to intracellular domains of PTPs that are provided by the present invention can bind to an intracellular domain of LAR, or both intracellular domains of CD45 and LAR. These antibodies of the present invention are believed to recognize consensus sequence(s) of phosphatase domains of PTPs, therefore, they are useful for analysis and quantitation of PTPs, for identification and detection of novel PTPs, and for obtaining novel phosphatases by cloning and the like. Furthermore, these antibodies can be extremely useful tools for elucidating signal transduction mechanisms of insulin, and various control mechanisms. Furthermore, the antibodies can be applied for developing
 40 useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onsets of arteriosclerosis and cardiac diseases.

45

50

55

SEQUENCE LISTING

5 <110> FUSO PHARMACEUTICAL INDUSTRIES, LTD.

<120> Antibody Specific for Intracellular Domain of
Protein Tyrosine Phosphatase

10 <130> 99P136W0

<160> 8

15 <210> 1

<211> 3467

<212> DNA

20 <213> Homo Sapiens

<220>

<221> CDS

25 <222> (6).. (1826)

<220>

<221> misc_feature

30 <222> (213).. (953)

<223> Tyrosine Phosphatase Domain 1

<220>

35 <221> misc_feature

<222> (1080).. (1826)

<223> Tyrosine Phosphatase Domain 2

40 <300>

<308> DDBJ/EMBL/GenBank Accession No. Y00815

<309> 1995-09-19

45 <400> 1

gatcc gga ctg aag gac tcc ttg ctg gcc cac tcc tct gac cct gtg gag 50

Gly Leu Lys Asp Ser Leu Leu Ala His Ser Ser Asp Pro Val Glu

1 5 10 15

50 atg cgg agg etc aac tac cag acc cca ggt atg cga gac cac cca ccc 98

Met Arg Arg Leu Asn Tyr Gln Thr Pro Gly Met Arg Asp His Pro Pro

55

	20	25	30	
	atc ccc atc acc gac ctg gcg gac aac atc gag cgc ctc aaa gcc aac			146
5	Ile Pro Ile Thr Asp Leu Ala Asp Asn Ile Glu Arg Leu Lys Ala Asn			
	35	40	45	
	gat ggc ctc aag ttc tcc cag gag tat gag tcc atc gac cct gga cag			194
	Asp Gly Leu Lys Phe Ser Gln Glu Tyr Glu Ser Ile Asp Pro Gly Gln			
10	50	55	60	
	cag ttc acg tgg gag aat tca aac ctg gag gtg aac aag ccc aag aac			242
	Gln Phe Thr Trp Glu Asn Ser Asn Leu Glu Val Asn Lys Pro Lys Asn			
	65	70	75	
15	cgc tat gcg aat gtc atc gcc tac gac cac tct cga gtc atc ctt acc			290
	Arg Tyr Ala Asn Val Ile Ala Tyr Asp His Ser Arg Val Ile Leu Thr			
	80	85	90	95
	tct atc gat ggc gtc ccc ggg agt gac tac atc aat gcc aac tac atc			338
20	Ser Ile Asp Gly Val Pro Gly Ser Asp Tyr Ile Asn Ala Asn Tyr Ile			
	100	105	110	
	gat ggc tac cgc aag cag aat gcc tac atc gcc acg cag ggc ccc ctg			386
	Asp Gly Tyr Arg Lys Gln Asn Ala Tyr Ile Ala Thr Gln Gly Pro Leu			
25	115	120	125	
	ccc gag acc atg ggc gat ttc tgg aga atg gtg tgg gaa cag cgc acg			434
	Pro Glu Thr Met Gly Asp Phe Trp Arg Met Val Trp Glu Gln Arg Thr			
	130	135	140	
30	gcc act gtg gtc atg atg aca cgg ctg gag gag aag tcc cgg gta aaa			482
	Ala Thr Val Val Met Met Thr Arg Leu Glu Glu Lys Ser Arg Val Lys			
	145	150	155	
	tgt gat cag tac tgg cca gcc cgt ggc acc gag acc tgt ggc ctt att			530
35	Cys Asp Gln Tyr Trp Pro Ala Arg Gly Thr Glu Thr Cys Gly Leu Ile			
	160	165	170	175
	cag gtg acc ctg ttg gac aca gtg gag ctg gcc aca tac act gtg cgc			578
	Gln Val Thr Leu Leu Asp Thr Val Glu Leu Ala Thr Tyr Thr Val Arg			
40	180	185	190	
	acc ttc gca ctc cac aag agt ggc tcc agt gag aag cgt gag ctg cgt			626
	Thr Phe Ala Leu His Lys Ser Gly Ser Ser Glu Lys Arg Glu Leu Arg			
	195	200	205	
45	cag ttt cag ttc atg gcc tgg cca gac cat gga gtt cct gag tac cca			674
	Gln Phe Gln Phe Met Ala Trp Pro Asp His Gly Val Pro Glu Tyr Pro			
	210	215	220	
	act ccc atc ctg gcc ttc cta cga cgg gtc aag gcc tgc aac ccc cta			722
50	Thr Pro Ile Leu Ala Phe Leu Arg Arg Val Lys Ala Cys Asn Pro Leu			
	225	230	235	

55

	gac gca ggg ccc atg gtg gtg cac tgc agc gcg ggc gtg ggc cgc acc	770
	Asp Ala Gly Pro Met Val Val His Cys Ser Ala Gly Val Gly Arg Thr	
5	240 245 250 255	
	ggc tgc ttc atc gtg att gat gcc atg ttg gag cgg atg aag cac gag	818
	Gly Cys Phe Ile Val Ile Asp Ala Met Leu Glu Arg Met Lys His Glu	
	260 265 270	
10	aag acg gtg gac atc tat ggc cac gtg acc tgc atg cga tca cag agg	866
	Lys Thr Val Asp Ile Tyr Gly His Val Thr Cys Met Arg Ser Gln Arg	
	275 280 285	
	aac tac atg gtg cag acg gag gac cag tac gtg ttc atc cat gag gcg	914
15	Asn Tyr Met Val Gln Thr Glu Asp Gln Tyr Val Phe Ile His Glu Ala	
	290 295 300	
	ctg ctg gag get gcc acg tgc ggc cac aca gag gtg cct gcc cgc aac	962
	Leu Leu Glu Ala Ala Thr Cys Gly His Thr Glu Val Pro Ala Arg Asn	
20	305 310 315	
	ctg tat gcc cac atc cag aag ctg ggc caa gtg cct cca ggg gag agt	1010
	Leu Tyr Ala His Ile Gln Lys Leu Gly Gln Val Pro Pro Gly Glu Ser	
	320 325 330 335	
25	gtg acc gcc atg gag ctc gag ttc aag ttg ctg gcc agc tcc aag gcc	1058
	Val Thr Ala Met Glu Leu Glu Phe Lys Leu Leu Ala Ser Ser Lys Ala	
	340 345 350	
	cac acg tcc cgc ttc atc agc gcc aac ctg ccc tgc aac aag ttc aag	1106
30	His Thr Ser Arg Phe Ile Ser Ala Asn Leu Pro Cys Asn Lys Phe Lys	
	355 360 365	
	aac cgg ctg gtg aac atc atg ccc tac gaa ttg acc cgt gtg tgt ctg	1154
	Asn Arg Leu Val Asn Ile Met Pro Tyr Glu Leu Thr Arg Val Cys Leu	
35	370 375 380	
	cag ccc atc cgt ggt gtg gag ggc tct gac tac atc aat gcc agc ttc	1202
	Gln Pro Ile Arg Gly Val Glu Gly Ser Asp Tyr Ile Asn Ala Ser Phe	
	385 390 395	
40	ctg gat ggt tat aga cag cag aag gcc tac ata gct aca cag ggg cct	1250
	Leu Asp Gly Tyr Arg Gln Gln Lys Ala Tyr Ile Ala Thr Gln Gly Pro	
	400 405 410 415	
	ctg gca gag agc acc gag gac ttc tgg cgc atg cta tgg gag cac aat	1298
45	Leu Ala Glu Ser Thr Glu Asp Phe Trp Arg Met Leu Trp Glu His Asn	
	420 425 430	
	tcc acc atc atc gtc atg ctg acc aag ctt cgg gag atg ggc agg gag	1346
	Ser Thr Ile Ile Val Met Leu Thr Lys Leu Arg Glu Met Gly Arg Glu	
50	435 440 445	
	aaa tgc cac cag tac tgg cca gca gag cgc tct gct cgc tac cag tac	1394

55

Lys Cys His Gln Tyr Trp Pro Ala Glu Arg Ser Ala Arg Tyr Gln Tyr
 450 455 460
 5 ttt gtt gtt gac ccg atg gct gag tac aac atg ccc cag tat atc ctg 1442
 Phe Val Val Asp Pro Met Ala Glu Tyr Asn Met Pro Gln Tyr Ile Leu
 465 470 475
 cgt gag ttc aag gtc acg gat gcc cgg gat ggg cag tca agg aca atc 1490
 Arg Glu Phe Lys Val Thr Asp Ala Arg Asp Gly Gln Ser Arg Thr Ile
 480 485 490 495
 cgg cag ttc cag ttc aca gac tgg cca gag cag ggc gtg ccc aag aca 1538
 Arg Gln Phe Gln Phe Thr Asp Trp Pro Glu Gln Gly Val Pro Lys Thr
 500 505 510
 ggc gag gga ttc att gac ttc atc ggg cag gtg cat aag acc aag gag 1586
 Gly Glu Gly Phe Ile Asp Phe Ile Gly Gln Val His Lys Thr Lys Glu
 515 520 525
 cag ttt gga cag gat ggg cct atc acg gtg cac tgc agt gct ggc gtg 1634
 Gln Phe Gly Gln Asp Gly Pro Ile Thr Val His Cys Ser Ala Gly Val
 530 535 540
 ggc cgc acc ggg gtg ttc atc act ctg agc atc gtc ctg gag cgc atg 1682
 Gly Arg Thr Gly Val Phe Ile Thr Leu Ser Ile Val Leu Glu Arg Met
 545 550 555
 cgc tat gag ggc gtg gtc gac atg ttt cag acc gtg aag acc ctg cgt 1730
 Arg Tyr Glu Gly Val Val Asp Met Phe Gln Thr Val Lys Thr Leu Arg
 560 565 570 575
 aca cag cgt cct gcc atg gtg cag aca gag gac cag tat cag ctg tgc 1778
 Thr Gln Arg Pro Ala Met Val Gln Thr Glu Asp Gln Tyr Gln Leu Cys
 580 585 590
 35 tac cgt gcg gcc ctg gag tac ctc ggc agc ttt gac cac tat gca acg 1826
 Tyr Arg Ala Ala Leu Glu Tyr Leu Gly Ser Phe Asp His Tyr Ala Thr
 595 600 605
 40 taactaccgc tccctctctc tccgccaccc ccgcctgtggg gctccggagg ggaccagct 1886
 cctctgagcc ataccgacca tcgtccagcc ctccctacgca gatgctgtca ctggcagagc 1946
 acagcccacg gggatcacag cgtttcagga acgttgccac accaatcaga gagcctagaa 2006
 catccctggg caagtggatg gccacagcagg caggcactgt ggccctctg tccaccagac 2066
 ccacctggag cccgcttcaa gctctctggt gcgctccgc atttctcatg cttctctca 2126
 45 tggggtgggg ttggggcaaa gcctcctttt taatacatta agtggggtag actgagggat 2186
 tttagcctct tccctctgat ttttctttc gcgaatccgt atctgcagaa tgggccactg 2246
 taggggttgg ggtttatttt gttttgtttt tttttttttt ttgtatgact tetgtgaag 2306
 gacagaacat tgccttctc gtgcagagct ggggtgccca gctgagcgg aggetcgcc 2366
 50 gtgggccggg aggcagtgt gatccggtg ctctccagc ccttcagacg agatcctgtt 2426
 tcagctaaat gcaggaaac tcaatgtttt ttaagtgtt gtttccctt taaagcctt 2486

55

5 ttttaggcca cattgacagt ggtagggcggg gagaagatag ggaacactca tccctggtcg 2546
 tctatcccag tgtgtgttta acattcacag cccagaacca cagatgtgtc tgggagagcc 2606
 tggcaaggca ttcctcatca ccatcgtgtt tgcaaaggtt aaaacaaaaa caaaaaacca 2666
 caaaaaataaa aaacaaaaaa aacaaaaaac ccaaaaaaaa aaaaaaaaag agtcagecct 2726
 tggcttctgc ttcaaaccct caagagggga agcaactccg tgtgcctggg gttcccagg 2786
 gagctgctgg ctgacctggg cccacagagc ctggttttgg tccccagcat tgcagtatgg 2846
 10 tgtgtgttt gtaggctgtg gggctctggc gtgtggccaa ggtgaatagc acaggttagg 2906
 gtgtgtgcca caccocatgc acctcagggc caagcggggg cgtggctggc ctttcaggtc 2966
 cagggcagtg ggcctggtag cacatgtctg tctcagagc aggggccaga tgattttcct 3026
 ccctggtttg cagctgtttt caaagccccc gataatcgt cttttccact ccaagatgcc 3086
 15 ctcataaacc aatgtggcaa gactactgga ctctatcaa tggactacta atcagtcctt 3146
 attatcccag ctgtctgagg ggcagggaga gcgcctcttc ctctgggcag cgctatctag 3206
 ataggtaagt gggggcgggg aagggtgcat agctgtttta gctgagggac gtggtgccga 3266
 cgtcccaaaa cctagctagg ctaagtcaag atcaacattc cagggttggg aatgttggat 3326
 20 gatgaacat tcatttttac ctgttgatg ctagtgtgt agagttcact gttgtacaca 3386
 gtctgttttc tatttgttaa gaaaaactac agcatcatig cataattctt gatgtaata 3446
 aatttgaata atcagatttc t 3467

25 <210> 2
 <211> 11
 <212> PRT
 <213> Unknown

30 <220>
 <223> Signature Motif Conserved in Phosphatase Domain of Known PTPs.

35 <220>
 <221> UNSURE
 <222> (1)
 40 <223> "Xaa"="Ile" or "Val".

45 <220>
 <221> UNSURE
 <222> (10)
 <223> "Xaa"="Ser" or "Thr".

50 <400> 2
 Xaa His Cys Xaa Ala Gly Xaa Xaa Arg Xaa Gly
 1 5 10

55

```

    <210> 3
    <211> 7702
5    <212> DNA
    <213> Homo Sapiens

    <220>
10   <221> CDS
    <222> (371).. (6064)

    <220>
15   <221> sig_peptide
    <222> (371).. (418)

    <220>
20   <221> mat_peptide
    <222> (419).. (6061)

    <220>
25   <221> misc_feature
    <222> (419).. (4120)
    <223> Extracellular Domain

30   <220>
    <221> misc_feature
    <222> (4121).. (4192)
35   <223> Transmembrane Domain

    <220>
    <221> misc_feature
40   <222> (4193).. (6061)
    <223> Cytoplasmic Domain

    <300>
45   <308> DDBJ/EMBL/GenBank Accession No. Y00815
    <309> 19-SEP-1995

    <400> 3
50   cgggagcggc gggagcggtg gcggcggcag aggcggcggc tccagcttcg gctccggctc   60
    gggctcgggc tccggctccg gctccggctc cggctccagc tcgggtggcg gtggcgggag   120

```

55

cgggaccagg tggaggcggc ggccggcagag gagtgggagc agcggcccta ggggcttgcg 180
 gggggacatg cggaccgacg gcccctggat aggcggaagg agtggaggcc ctgggtcccc 240
 5 gccccttggtg ctgagtatcc agcaagagtg accgggggtga agaagcaaag actcggttga 300
 ttgtcctggg ctgtggctgg ctgtggagct agagccctgg atggccctg agccagcccc 360
 agggaggacg atg gtg ccc ctt gtg cct gca ctg gtg atg ctt ggt ttg 409
 Met Val Pro Leu Val Pro Ala Leu Val Met Leu Gly Leu
 -15 -10 -5
 10 gtg gca ggc gcc cat ggt gac agc aaa cct gtc ttc att aaa gtc cct 457
 Val Ala Gly Ala His Gly Asp Ser Lys Pro Val Phe Ile Lys Val Pro
 1 5 10
 15 gag gac cag act ggg ctg tca gga ggg gta gcc tcc ttc gtg tgc caa 505
 Glu Asp Gln Thr Gly Leu Ser Gly Gly Val Ala Ser Phe Val Cys Gln
 15 20 25
 20 gct aca gga gaa ccc aag ccg cgc atc aca tgg atg aag aag ggg aag 553
 Ala Thr Gly Glu Pro Lys Pro Arg Ile Thr Trp Met Lys Lys Gly Lys
 30 35 40 45
 aaa gtc agc tcc cag cgc ttc gag gtc att gag ttt gat gat ggg gca 601
 Lys Val Ser Ser Gln Arg Phe Glu Val Ile Glu Phe Asp Asp Gly Ala
 50 55 60
 25 ggg tca gtg ctt cgg atc cag cca ttg cgg gtg cag cga gat gaa gcc 649
 Gly Ser Val Leu Arg Ile Gln Pro Leu Arg Val Gln Arg Asp Glu Ala
 65 70 75
 30 atc tat gag tgt aca gct act aac agc ctg ggt gag atc aac act agt 697
 Ile Tyr Glu Cys Thr Ala Thr Asn Ser Leu Gly Glu Ile Asn Thr Ser
 80 85 90
 35 gcc aag ctc tca gtg ctc gaa gag gaa cag ctg ccc cct ggg ttc cct 745
 Ala Lys Leu Ser Val Leu Glu Glu Glu Gln Leu Pro Pro Gly Phe Pro
 95 100 105
 tcc atc gac atg ggg cct cag ctg aag gtg gtg gag aag gca cgc aca 793
 Ser Ile Asp Met Gly Pro Gln Leu Lys Val Val Glu Lys Ala Arg Thr
 110 115 120 125
 40 gcc acc atg cta tgt gcc gca ggc gga aat cca gac cct gag att tct 841
 Ala Thr Met Leu Cys Ala Ala Gly Gly Asn Pro Asp Pro Glu Ile Ser
 130 135 140
 45 tgg ttc aag gac ttc ctt cct gta gac cct gcc acg agc aac ggc cgc 889
 Trp Phe Lys Asp Phe Leu Pro Val Asp Pro Ala Thr Ser Asn Gly Arg
 145 150 155
 50 atc aag cag ctg cgt tca ggt gcc ttg cag ata gag agc agt gag gaa 937
 Ile Lys Gln Leu Arg Ser Gly Ala Leu Gln Ile Glu Ser Ser Glu Glu
 160 165 170

55

	tcc gac caa ggc aag tac gag tgt gtg gcg acc aac tcg gca ggc aca	985
	Ser Asp Gln Gly Lys Tyr Glu Cys Val Ala Thr Asn Ser Ala Gly Thr	
5	175 180 185	
	cgt tac tca gcc cct gcg aac ctg tat gtg cga gtg cgc cgc gtg gct	1033
	Arg Tyr Ser Ala Pro Ala Asn Leu Tyr Val Arg Val Arg Arg Val Ala	
	190 195 200 205	
10	cct cgt ttc tcc atc cct ccc agc agc cag gag gtg atg cca ggc ggc	1081
	Pro Arg Phe Ser Ile Pro Pro Ser Ser Gln Glu Val Met Pro Gly Gly	
	210 215 220	
	agc gtg aac ctg aca tgc gtg gca gtg ggt gca ccc atg ccc tac gtg	1129
15	Ser Val Asn Leu Thr Cys Val Ala Val Gly Ala Pro Met Pro Tyr Val	
	225 230 235	
	aag tgg atg atg ggg gcc gag gag ctc acc aag gag gat gag atg cca	1177
	Lys Trp Met Met Gly Ala Glu Glu Leu Thr Lys Glu Asp Glu Met Pro	
20	240 245 250	
	gtt ggc cgc aac gtc ctg gag ctc agc aat gtc gta cgc tct gcc aac	1225
	Val Gly Arg Asn Val Leu Glu Leu Ser Asn Val Val Arg Ser Ala Asn	
	255 260 265	
25	tac acc tgt gtg gcc atc tcc tcg ctg gcc atg atc gag gcc aca gcc	1273
	Tyr Thr Cys Val Ala Ile Ser Ser Leu Gly Met Ile Glu Ala Thr Ala	
	270 275 280 285	
	cag gtc aca gtg aaa gct ctt cca aag cct ccg att gat ctt gtg gtg	1321
30	Gln Val Thr Val Lys Ala Leu Pro Lys Pro Pro Ile Asp Leu Val Val	
	290 295 300	
	aca gag aca act gcc acc agt gtc acc ctc acc tgg gac tct ggg aac	1369
	Thr Glu Thr Thr Ala Thr Ser Val Thr Leu Thr Trp Asp Ser Gly Asn	
35	305 310 315	
	tcg gag cct gta acc tac tat ggc atc cag tac cgc gca gcg ggc acg	1417
	Ser Glu Pro Val Thr Tyr Tyr Gly Ile Gln Tyr Arg Ala Ala Gly Thr	
	320 325 330	
40	gag ggc ccc ttt cag gag gtg gat ggt gtg gcc acc acc cgc tac agc	1465
	Glu Gly Pro Phe Gln Glu Val Asp Gly Val Ala Thr Thr Arg Tyr Ser	
	335 340 345	
45	att ggc ggc ctc agc cct ttc tcg gaa tat gcc ttc cgc gtg ctg gcg	1513
	Ile Gly Gly Leu Ser Pro Phe Ser Glu Tyr Ala Phe Arg Val Leu Ala	
	350 355 360 365	
	gtg aac agc atc ggg cga ggg ccg ccc agc gag gca gtg cgg gca cgc	1561
	Val Asn Ser Ile Gly Arg Gly Pro Pro Ser Glu Ala Val Arg Ala Arg	
50	370 375 380	
	acg gga gaa cag gcg ccc tcc agc cca ccg cgc cgc gtg cag gca cgc	1609

55

Thr Gly Glu Gln Ala Pro Ser Ser Pro Pro Arg Arg Val Gln Ala Arg
 385 390 395
 5 atg ctg agc gcc agc acc atg ctg gtg cag tgg gag cct ccc gag gag 1657
 Met Leu Ser Ala Ser Thr Met Leu Val Gln Trp Glu Pro Pro Glu Glu
 400 405 410
 ccc aac gcc ctg gtg cgg gga tac cgc gtc tac tat act ccg gac tcc 1705
 10 Pro Asn Gly Leu Val Arg Gly Tyr Arg Val Tyr Tyr Thr Pro Asp Ser
 415 420 425
 cgc cgc ccc ccg aac gcc tgg cac aag cac aac acc gac gcg ggg ctc 1753
 Arg Arg Pro Pro Asn Ala Trp His Lys His Asn Thr Asp Ala Gly Leu
 15 430 435 440 445
 ctc acg acc gtg ggc agc ctg ctg cct gcc atc acc tac agc ctg cgc 1801
 Leu Thr Thr Val Gly Ser Leu Leu Pro Gly Ile Thr Tyr Ser Leu Arg
 450 455 460
 20 gtg ctt gcc ttc acc gcc gtg ggc gat gcc cct ccc agc ccc acc atc 1849
 Val Leu Ala Phe Thr Ala Val Gly Asp Gly Pro Pro Ser Pro Thr Ile
 465 470 475
 cag gtc aag acg cag cag gga gtg cct gcc cag ccc gcg gac ttc cag 1897
 25 Gln Val Lys Thr Gln Gln Gly Val Pro Ala Gln Pro Ala Asp Phe Gln
 480 485 490
 gcc gag gtg gag tcg gac acc agg atc cag ctc tcg tgg ctg ctg ccc 1945
 Ala Glu Val Glu Ser Asp Thr Arg Ile Gln Leu Ser Trp Leu Leu Pro
 30 495 500 505
 cct cag gag cgg atc atc atg tat gaa ctg gtg tac tgg gcg gca gag 1993
 Pro Gln Glu Arg Ile Ile Met Tyr Glu Leu Val Tyr Trp Ala Ala Glu
 510 515 520 525
 35 gac gaa gac caa cag cac aag gtc acc ttc gac cca acc tcc tcc tac 2041
 Asp Glu Asp Gln Gln His Lys Val Thr Phe Asp Pro Thr Ser Ser Tyr
 530 535 540
 aca cta gag gac ctg aag cct gac aca ctc tac cgc ttc cag ctg gct 2089
 40 Thr Leu Glu Asp Leu Lys Pro Asp Thr Leu Tyr Arg Phe Gln Leu Ala
 545 550 555
 gca cgc tcg gat atg ggg gtg ggc gtc ttc acc ccc acc att gag gcc 2137
 Ala Arg Ser Asp Met Gly Val Gly Val Phe Thr Pro Thr Ile Glu Ala
 45 560 565 570
 cgc aca gcc cag tcc acc ccc tcc gcc cct ccc cag aag gtg atg tgt 2185
 Arg Thr Ala Gln Ser Thr Pro Ser Ala Pro Pro Gln Lys Val Met Cys
 575 580 585
 50 gtg agc atg gcc tcc acc acg gtc cgg gta agt tgg gtc ccg ccg cct 2233
 Val Ser Met Gly Ser Thr Thr Val Arg Val Ser Trp Val Pro Pro Pro

55

	590	595	600	605	
	gcc gac agc cgc aac ggc gtt atc acc cag tac tcc gtg gcc cac gag				2281
5	Ala Asp Ser Arg Asn Gly Val Ile Thr Gln Tyr Ser Val Ala His Glu				
	610	615	620		
	gcg gtg gac ggc gag gac cgc ggg cgg cat gtg gtg gat ggc atc agc				2329
	Ala Val Asp Gly Glu Asp Arg Gly Arg His Val Val Asp Gly Ile Ser				
10	625	630	635		
	cgt gag cac tcc agc tgg gac ctg gtg ggc ctg gag aag tgg acg gag				2377
	Arg Glu His Ser Ser Trp Asp Leu Val Gly Leu Glu Lys Trp Thr Glu				
	640	645	650		
15	tac cgg gtg tgg gtg cgg gca cac aca gac gtg ggc ccc ggc ccc gag				2425
	Tyr Arg Val Trp Val Arg Ala His Thr Asp Val Gly Pro Gly Pro Glu				
	655	660	665		
	agc agc ccg gtg ctg gtg cgc acc gat gag gac gtg ccc agc ggg cct				2473
20	Ser Ser Pro Val Leu Val Arg Thr Asp Glu Asp Val Pro Ser Gly Pro				
	670	675	680	685	
	ccg cgg aag gtg gag gtg gag cca ctg aac tcc act gct gtg cat gtc				2521
	Pro Arg Lys Val Glu Val Glu Pro Leu Asn Ser Thr Ala Val His Val				
25	690	695	700		
	tac tgg aag ctg cct gtc ccc agc aag cag cat ggc cag atc cgc ggc				2569
	Tyr Trp Lys Leu Pro Val Pro Ser Lys Gln His Gly Gln Ile Arg Gly				
	705	710	715		
30	tac cag gtc acc tac gtg cgg ctg gag aat ggc gag ccc cgt gga etc				2617
	Tyr Gln Val Thr Tyr Val Arg Leu Glu Asn Gly Glu Pro Arg Gly Leu				
	720	725	730		
	ccc atc atc caa gac gtc atg cta gcc gag gcc cag tgg cgg cca gag				2665
35	Pro Ile Ile Gln Asp Val Met Leu Ala Glu Ala Gln Trp Arg Pro Glu				
	735	740	745		
	gag tcc gag gac tat gaa acc act atc agc ggc ctg acc ccg gag acc				2713
	Glu Ser Glu Asp Tyr Glu Thr Thr Ile Ser Gly Leu Thr Pro Glu Thr				
40	750	755	760	765	
	acc tac tcc gtt act gtt gct gcc tat acc acc aag ggg gat ggt gcc				2761
	Thr Tyr Ser Val Thr Val Ala Ala Tyr Thr Thr Lys Gly Asp Gly Ala				
	770	775	780		
45	cgc agc aag ccc aaa att gtc act aca aca ggt gca gtc cca ggc cgg				2809
	Arg Ser Lys Pro Lys Ile Val Thr Thr Thr Gly Ala Val Pro Gly Arg				
	785	790	795		
	ccc acc atg atg atc agc acc acg gcc atg aac act gcg ctg etc cag				2857
50	Pro Thr Met Met Ile Ser Thr Thr Ala Met Asn Thr Ala Leu Leu Gln				
	800	805	810		

55

tgg cac cca ccc aag gaa ctg cct ggc gag ctg ctg ggc tac cgg ctg 2905
 Trp His Pro Pro Lys Glu Leu Pro Gly Glu Leu Leu Gly Tyr Arg Leu
 5 815 820 825
 cag tac tgc cgg gcc gac gag gcg cgg ccc aac acc ata gat ttc ggc 2953
 Gln Tyr Cys Arg Ala Asp Glu Ala Arg Pro Asn Thr Ile Asp Phe Gly
 830 835 840 845
 10 aag gat gac cag cac ttc aca gtc acc ggc ctg cac aag ggg acc acc 3001
 Lys Asp Asp Gln His Phe Thr Val Thr Gly Leu His Lys Gly Thr Thr
 850 855 860
 tac atc ttc cgg ctt gct gcc aag aac cgg gct ggc ttg ggt gag gag 3049
 15 Tyr Ile Phe Arg Leu Ala Ala Lys Asn Arg Ala Gly Leu Gly Glu Glu
 865 870 875
 ttc gag aag gag atc agg acc ccc gag gac ctg ccc agc ggc ttc ccc 3097
 Phe Glu Lys Glu Ile Arg Thr Pro Glu Asp Leu Pro Ser Gly Phe Pro
 20 880 885 890
 caa aac ctg cat gtg aca gga ctg acc acg tct acc aca gaa ctg gcc 3145
 Gln Asn Leu His Val Thr Gly Leu Thr Thr Ser Thr Thr Glu Leu Ala
 895 900 905
 25 tgg gac ccg cca gtg ctg gcg gag agg aac ggg cgc atc atc agc tac 3193
 Trp Asp Pro Pro Val Leu Ala Glu Arg Asn Gly Arg Ile Ile Ser Tyr
 910 915 920 925
 acc gtg gtg ttc cga gac atc aac agc caa cag gag ctg cag aac atc 3241
 30 Thr Val Val Phe Arg Asp Ile Asn Ser Gln Gln Glu Leu Gln Asn Ile
 930 935 940
 acg aca gac acc cgc ttt acc ctt act ggc ctc aag cca gac acc act 3289
 Thr Thr Asp Thr Arg Phe Thr Leu Thr Gly Leu Lys Pro Asp Thr Thr
 35 945 950 955
 tac gac atc aag gtc cgc gca tgg acc agc aaa ggc tct ggc cca ctc 3337
 Tyr Asp Ile Lys Val Arg Ala Trp Thr Ser Lys Gly Ser Gly Pro Leu
 960 965 970
 40 agc ccc agc atc cag tcc cgg acc atg ccg gtg gag caa gtg ttt gcc 3385
 Ser Pro Ser Ile Gln Ser Arg Thr Met Pro Val Glu Gln Val Phe Ala
 975 980 985
 aag aac ttc cgg gtg gcg gct gca atg aag acg tct gtg ctg ctc agc 3433
 45 Lys Asn Phe Arg Val Ala Ala Ala Met Lys Thr Ser Val Leu Leu Ser
 990 995 1000 1005
 tgg gag gtt ccc gac tcc tat aag tca gct gtg ccc ttt aag att ctg 3481
 Trp Glu Val Pro Asp Ser Tyr Lys Ser Ala Val Pro Phe Lys Ile Leu
 50 1010 1015 1020
 tac aat ggg cag agt gtg gag gtg gac ggg cac tcg atg cgg aag ctg 3529

55

	Tyr Asn Gly Gln Ser Val Glu Val Asp Gly His Ser Met Arg Lys Leu	
	1025 1030 1035	
5	atc gca gac ctg cag ccc aac aca gag tac tcg ttt gtg ctg atg aac	3577
	Ile Ala Asp Leu Gln Pro Asn Thr Glu Tyr Ser Phe Val Leu Met Asn	
	1040 1045 1050	
	cgt ggc agc agc gca ggg ggc ctg cag cac ctg gtg tcc atc cgc aca	3625
10	Arg Gly Ser Ser Ala Gly Gly Leu Gln His Leu Val Ser Ile Arg Thr	
	1055 1060 1065	
	gcc ccc gac ctc ctg cct cac aag ccg ctg cct gcc tct gcc tac ata	3673
	Ala Pro Asp Leu Leu Pro His Lys Pro Leu Pro Ala Ser Ala Tyr Ile	
15	1070 1075 1080 1085	
	gag gac ggc cgc ttc gat ctc tcc atg ccc cat gtg caa gac ccc tcg	3721
	Glu Asp Gly Arg Phe Asp Leu Ser Met Pro His Val Gln Asp Pro Ser	
	1090 1095 1100	
20	ctt gtc agg tgg ttc tac att gtt gtg gta ccc att gac cgt gtg ggc	3769
	Leu Val Arg Trp Phe Tyr Ile Val Val Pro Ile Asp Arg Val Gly	
	1105 1110 1115	
	ggg agc atg ctg acg cca agg tgg agc aca ccc gag gaa ctg gag ctg	3817
25	Gly Ser Met Leu Thr Pro Arg Trp Ser Thr Pro Glu Glu Leu Glu Leu	
	1120 1125 1130	
	gac gag ctt cta gaa gcc atc gag caa ggc gga gag gag cag cgg cgg	3865
	Asp Glu Leu Leu Glu Ala Ile Glu Gln Gly Gly Glu Glu Gln Arg Arg	
30	1135 1140 1145	
	cgg cgg cgg cag gca gaa cgt ctg aag cca tat gtg gct gct caa ctg	3913
	Arg Arg Arg Gln Ala Glu Arg Leu Lys Pro Tyr Val Ala Ala Gln Leu	
	1150 1155 1160 1165	
35	gat gtg ctc ccg gag acc ttt acc ttg ggg gac aag aag aac tac cgg	3961
	Asp Val Leu Pro Glu Thr Phe Thr Leu Gly Asp Lys Lys Asn Tyr Arg	
	1170 1175 1180	
	ggc ttc tac aac egg ccc ctg tct ccg gac ttg agc tac cag tgc ttt	4009
40	Gly Phe Tyr Asn Arg Pro Leu Ser Pro Asp Leu Ser Tyr Gln Cys Phe	
	1185 1190 1195	
	gtg ctt gcc tcc ttg aag gaa ccc atg gac cag aag cgc tat gcc tcc	4057
	Val Leu Ala Ser Leu Lys Glu Pro Met Asp Gln Lys Arg Tyr Ala Ser	
45	1200 1205 1210	
	agc ccc tac tcg gat gag atc gtg gtc cag gtg aca cca gcc cag cag	4105
	Ser Pro Tyr Ser Asp Glu Ile Val Val Gln Val Thr Pro Ala Gln Gln	
	1215 1220 1225	
50	cag gag gag ccg gag atg ctg tgg gtg acg ggt ccc gtg ctg gca gtc	4153
	Gln Glu Glu Pro Glu Met Leu Trp Val Thr Gly Pro Val Leu Ala Val	

55

	1230	1235	1240	1245	
	atc ctc atc atc ctc att gtc atc gcc atc ctc ttg ttc aaa agg aaa				4201
5	Ile Leu Ile Ile Leu Ile Val Ile Ala Ile Leu Leu Phe Lys Arg Lys				
	1250	1255	1260		
	agg acc cac tct ccg tcc tct aag gat gag cag tcg atc gga ctg aag				4249
	Arg Thr His Ser Pro Ser Ser Lys Asp Glu Gln Ser Ile Gly Leu Lys				
10	1265	1270	1275		
	gac tcc ttg ctg gcc cac tcc tct gac cct gtg gag atg cgg agg ctc				4297
	Asp Ser Leu Leu Ala His Ser Ser Asp Pro Val Glu Met Arg Arg Leu				
	1280	1285	1290		
15	aac tac cag acc cca ggt atg cga gac cac cca ccc atc ccc atc acc				4345
	Asn Tyr Gln Thr Pro Gly Met Arg Asp His Pro Pro Ile Pro Ile Thr				
	1295	1300	1305		
	gac ctg gcg gac aac atc gag cgc ctc aaa gcc aac gat ggc ctc aag				4393
20	Asp Leu Ala Asp Asn Ile Glu Arg Leu Lys Ala Asn Asp Gly Leu Lys				
	1310	1315	1320	1325	
	ttc tcc cag gag tat gag tcc atc gac cct gga cag cag ttc acg tgg				4441
	Phe Ser Gln Glu Tyr Glu Ser Ile Asp Pro Gly Gln Gln Phe Thr Trp				
25	1330	1335	1340		
	gag aat tca aac ctg gag gtg aac aag ccc aag aac cgc tat gcg aat				4489
	Glu Asn Ser Asn Leu Glu Val Asn Lys Pro Lys Asn Arg Tyr Ala Asn				
	1345	1350	1355		
30	gtc atc gcc tac gac cac tct cga gtc atc ctt acc tct atc gat ggc				4537
	Val Ile Ala Tyr Asp His Ser Arg Val Ile Leu Thr Ser Ile Asp Gly				
	1360	1365	1370		
	gtc ccc ggg agt gac tac atc aat gcc aac tac atc gat ggc tac cgc				4585
35	Val Pro Gly Ser Asp Tyr Ile Asn Ala Asn Tyr Ile Asp Gly Tyr Arg				
	1375	1380	1385		
	aag cag aat gcc tac atc gcc acg cag ggc ccc ctg ccc gag acc atg				4633
	Lys Gln Asn Ala Tyr Ile Ala Thr Gln Gly Pro Leu Pro Glu Thr Met				
40	1390	1395	1400	1405	
	ggc gat ttc tgg aga atg gtg tgg gaa cag cgc acg gcc act gtg gtc				4681
	Gly Asp Phe Trp Arg Met Val Trp Glu Gln Arg Thr Ala Thr Val Val				
	1410	1415	1420		
45	atg atg aca cgg ctg gag gag aag tcc cgg gta aaa tgt gat cag tac				4729
	Met Met Thr Arg Leu Glu Glu Lys Ser Arg Val Lys Cys Asp Gln Tyr				
	1425	1430	1435		
	tgg cca gcc cgt ggc acc gag acc tgt ggc ctt att cag gtg acc ctg				4777
50	Trp Pro Ala Arg Gly Thr Glu Thr Cys Gly Leu Ile Gln Val Thr Leu				
	1440	1445	1450		

55

	ttg gac aca gtg gag ctg gcc aca tac act gtg cgc acc ttc gca etc	4825
	Leu Asp Thr Val Glu Leu Ala Thr Tyr Thr Val Arg Thr Phe Ala Leu	
5	1455 1460 1465	
	cac aag agt ggc tcc agt gag aag cgt gag ctg cgt cag ttt cag ttc	4873
	His Lys Ser Gly Ser Ser Glu Lys Arg Glu Leu Arg Gln Phe Gln Phe	
10	1470 1475 1480 1485	
	atg gcc tgg cca gac cat gga gtt cct gag tac cca act ccc atc ctg	4921
	Met Ala Trp Pro Asp His Gly Val Pro Glu Tyr Pro Thr Pro Ile Leu	
	1490 1495 1500	
15	gcc ttc cta cga cgg gtc aag gcc tgc aac ccc cta gac gca ggg ccc	4969
	Ala Phe Leu Arg Arg Val Lys Ala Cys Asn Pro Leu Asp Ala Gly Pro	
	1505 1510 1515	
	atg gtg gtg cac tgc agc gcg ggc gtg ggc cgc acc ggc tgc ttc atc	5017
	Met Val Val His Cys Ser Ala Gly Val Gly Arg Thr Gly Cys Phe Ile	
20	1520 1525 1530	
	gtg att gat gcc atg ttg gag cgg atg aag cac gag aag acg gtg gac	5065
	Val Ile Asp Ala Met Leu Glu Arg Met Lys His Glu Lys Thr Val Asp	
	1535 1540 1545	
25	atc tat ggc cac gtg acc tgc atg cga tca cag agg aac tac atg gtg	5113
	Ile Tyr Gly His Val Thr Cys Met Arg Ser Gln Arg Asn Tyr Met Val	
	1550 1555 1560 1565	
30	cag acg gag gac cag tac gtg ttc atc cat gag gcg ctg ctg gag gct	5161
	Gln Thr Glu Asp Gln Tyr Val Phe Ile His Glu Ala Leu Leu Glu Ala	
	1570 1575 1580	
	gcc acg tgc ggc cac aca gag gtg cct gcc cgc aac ctg tat gcc cac	5209
	Ala Thr Cys Gly His Thr Glu Val Pro Ala Arg Asn Leu Tyr Ala His	
35	1585 1590 1595	
	atc cag aag ctg ggc caa gtg cct cca ggg gag agt gtg acc gcc atg	5257
	Ile Gln Lys Leu Gly Gln Val Pro Pro Gly Glu Ser Val Thr Ala Met	
	1600 1605 1610	
40	gag ctc gag ttc aag ttg ctg gcc agc tcc aag gcc cac acg tcc cgc	5305
	Glu Leu Glu Phe Lys Leu Leu Ala Ser Ser Lys Ala His Thr Ser Arg	
	1615 1620 1625	
45	ttc atc agc gcc aac ctg ccc tgc aac aag ttc aag aac cgg ctg gtg	5353
	Phe Ile Ser Ala Asn Leu Pro Cys Asn Lys Phe Lys Asn Arg Leu Val	
	1630 1635 1640 1645	
	aac atc atg ccc tac gaa ttg acc cgt gtg tgt ctg cag ccc atc cgt	5401
	Asn Ile Met Pro Tyr Glu Leu Thr Arg Val Cys Leu Gln Pro Ile Arg	
50	1650 1655 1660	
	ggg gtg gag ggc tct gac tac atc aat gcc agc ttc ctg gat ggt tat	5449

55

	Gly Val Glu Gly Ser Asp Tyr Ile Asn Ala Ser Phe Leu Asp Gly Tyr	
	1665 1670 1675	
5	aga cag cag aag gcc tac ata gct aca cag ggg cct ctg gca gag agc	5497
	Arg Gln Gln Lys Ala Tyr Ile Ala Thr Gln Gly Pro Leu Ala Glu Ser	
	1680 1685 1690	
	acc gag gac ttc tgg cgc atg cta tgg gag cac aat tcc acc atc atc	5545
10	Thr Glu Asp Phe Trp Arg Met Leu Trp Glu His Asn Ser Thr Ile Ile	
	1695 1700 1705	
	gtc atg ctg acc aag ctt cgg gag atg ggc agg gag aaa tgc cac cag	5593
	Val Met Leu Thr Lys Leu Arg Glu Met Gly Arg Glu Lys Cys His Gln	
15	1710 1715 1720 1725	
	tac tgg cca gca gag cgc tct gct cgc tac cag tac ttt gtt gtt gac	5641
	Tyr Trp Pro Ala Glu Arg Ser Ala Arg Tyr Gln Tyr Phe Val Val Asp	
	1730 1735 1740	
20	ccg atg gct gag tac aac atg ccc cag tat atc ctg cgt gag ttc aag	5689
	Pro Met Ala Glu Tyr Asn Met Pro Gln Tyr Ile Leu Arg Glu Phe Lys	
	1745 1750 1755	
	gtc acg gat gcc cgg gat ggg cag tca agg aca atc cgg cag ttc cag	5737
25	Val Thr Asp Ala Arg Asp Gly Gln Ser Arg Thr Ile Arg Gln Phe Gln	
	1760 1765 1770	
	ttc aca gac tgg cca gag cag ggc gtg ccc aag aca ggc gag gga ttc	5785
	Phe Thr Asp Trp Pro Glu Gln Gly Val Pro Lys Thr Gly Glu Gly Phe	
30	1775 1780 1785	
	att gac ttc atc ggg cag gtg cat aag acc aag gag cag ttt gga cag	5833
	Ile Asp Phe Ile Gly Gln Val His Lys Thr Lys Glu Gln Phe Gly Gln	
	1790 1795 1800 1805	
35	gat ggg cct atc acg gtg cac tgc agt gct ggc gtg ggc cgc acc ggg	5881
	Asp Gly Pro Ile Thr Val His Cys Ser Ala Gly Val Gly Arg Thr Gly	
	1810 1815 1820	
	gtg ttc atc act ctg agc atc gtc ctg gag cgc atg cgc tat gag ggc	5929
40	Val Phe Ile Thr Leu Ser Ile Val Leu Glu Arg Met Arg Tyr Glu Gly	
	1825 1830 1835	
	gtg gtc gac atg ttt cag acc gtg aag acc ctg cgt aca cag cgt cct	5977
	Val Val Asp Met Phe Gln Thr Val Lys Thr Leu Arg Thr Gln Arg Pro	
45	1840 1845 1850	
	gcc atg gtg cag aca gag gac cag tat cag ctg tgc tac cgt gcg gcc	6025
	Ala Met Val Gln Thr Glu Asp Gln Tyr Gln Leu Cys Tyr Arg Ala Ala	
	1855 1860 1865	
50	ctg gag tac etc ggc agc ttt gac cac tat gca acg taactaccgc	6071
	Leu Glu Tyr Leu Gly Ser Phe Asp His Tyr Ala Thr	1881
55		

1870 1875 1880
 tccccctctcc tccgccaccc ccgccgtggg gctccggagg ggacccagct cctctgagcc 6131
 5 ataccgacca tegtccagcc ctctacgca gatgtgtca ctggcagagc acagcccacg 6191
 gggatcacag cgtttcagga acgttgccac accaatcaga gaggcctaga catccctggg 6251
 caagtggatg gccacagagg caggcactgt ggcccttctg tccaccagac ccacctggag 6311
 cccgcttcaa gctctctgtt gcgctccgcg atttctcatg cttcttctca tggggtgggg 6371
 10 ttggggcaaa gcctcctttt taatacatta agtggggtag actgagggat tttagcctct 6431
 tccctctgat ttttccttcc gcgaatccgt atctgcagaa tgggccactg taggggttgg 6491
 ggtttatitt gttttgtttt tttttttttt ttgtatgaet tctgtgaag gacagaacat 6551
 tgccttcctc gtgcagagct ggggctgcca gcctgagcgg aggctcgccc gtgggcccgg 6611
 15 aggcagtgtc gatccggctg ctctccagc ccttcagacg agatcctgtt tcagctaaat 6671
 gcagggaac tcaatgtttt ttttaagttt gttttccctt taaagcctt ttttaggcca 6731
 cattgacagt ggtgggcccg gagaagatag ggaacactca tccctggctg tetatcccag 6791
 tgtgtgttta acattcacag cccagaacca cagatgtgtc tgggagagcc tggcaaggca 6851
 20 ttctcatca ccatcgtgtt tgcaaaaggtt aaaacaaaaa caaaaaacca caaaaataaa 6911
 aaacaaaaaa aacaaaaaac ccaaaaaaaa aaaaaaaaag agtcagccct tggttctgc 6971
 ttcaaacct caagagggga agcaactccg tgtgcctggg gtccccagg gagctgtcg 7031
 ctgacctggg cccacagagc ctggcttggg tccccagcat tgcagtatgg tgtggtgtt 7091
 25 gtaggtgtg gggctgtgct gtgtggccaa ggtgaatagc acaggttagg gtgtgtgcca 7151
 caccctatgc acctcagggc caagcggggg cgtggtggc ctttcaggtc caggccagt 7211
 ggcttggtag cacatgtctg tctcagagc aggggccaga tgattttcct ccttggtttg 7271
 cagctgtttt caaagccccc gataatcgt cttttccact ccaagatgcc ctcataaacc 7331
 30 aatgtggcaa gactactgga cttctatcaa tggtaacta atcagtcctt attatcccag 7391
 ctgtctgagg ggcagggaga gcgctcttc cctgggcag cgctatctag ataggttaagt 7451
 gggggcgggg aagggtgcat agctgtttta gctgagggac gtggtgccga cgtcccaaaa 7511
 cctagctagg ctaagtcaag atcaacatc cagggttgg aatgttggat gatgaaacat 7571
 35 tcatttttac ctgtgtgatg ctagtgtgt agagttcact gttgtacaca gtctgttttc 7631
 tatttgttaa gaaaactac agcatcattg cataattctt gatggttaata aatttgaata 7691
 atcagatttc t 7702

40 <210> 4
 <211> 12
 <212> PRT
 45 <213> Unknown

<220>
 <223> Identical Sequence in Phosphatase Domain 1 of LAR and
 50 CD45

<400> 4

55

Val Val His Cys Ser Ala Gly Val Gly Arg Thr Gly
 1 5 10

5

<210> 5

<211> 6

<212> PRT

10

<213> Unknown

<220>

15

<223> Consensus Amino Acid Sequence in Cytoplasmic Domain of
 Known PTPs.

<220>

20

<221> UNSURE

<222> (3)

<223> "Xaa"="Arg", "Glu" or "Leu".

25

<220>

<221> UNSURE

<222> (5)

<223> "Xaa"="Val", "Ile" or "Cys".

30

<400> 5

Phe Trp Xaa Met Xaa Trp

1 5

35

<210> 6

<211> 7

<212> PRT

40

<213> Unknown

<220>

45

<223> Consensus Amino Acid Sequence in Cytoplasmic Domain of
 Known PTPs.

<220>

50

<221> UNSURE

<222> (3)

<223> "Xaa"="Ala" or "Asp".

55

<220>

<221> UNSURE

5 <222> (4)

<223> "Xaa"="Gln", "Glu" or "Lys".

<400> 6

10 Lys Cys Xaa Xaa Tyr Trp Pro

1 5

<210> 7

15 <211> 6

<212> PRT

<213> Unknown

20 <220>

<223> Consensus Amino Acid Sequence in Cytoplasmic Domain of
Known PTPs.

25 <220>

<221> UNSURE

<222> (4)

30 <223> "Xaa"="His" or "Phe".

<400> 7

Trp Pro Asp Xaa Gly Val

35 1 5

<210> 8

<211> 14

40 <212> PRT

<213> Unknown

<220>

45 <223> Consensus Amino Acid Sequence in Cytoplasmic Domain of
Known PTPs.

<220>

50 <221> UNSURE

<222> (3)

<223> "Xaa"="Ile" or "Val".

55

<220>

<221> UNSURE

<222> (4)

<223> "Xaa"="Ile" or "Val".

<220>

<221> UNSURE

<222> (13)

<223> "Xaa"="Thr" or "Ser".

<400> 8

Pro	Xaa	Xaa	Xaa	His	Cys	Xaa	Ala	Gly	Xaa	Gly	Arg	Xaa	Gly
1				5				10					

Claims

1. An antibody having specificity to intracellular domains of two or more kinds of protein tyrosine phosphatases.
2. The antibody according to claim 1, wherein at least one of said protein tyrosine phosphatase is a receptor type protein tyrosine phosphatase.
3. The antibody according to claim 2, wherein said receptor type protein tyrosine phosphatase is LAR and/or CD45.
4. The antibody according to claim 2, wherein said receptor type protein tyrosine phosphatase is LAR and CD45.
5. The antibody according to any of claims 1-4 having specificity to phosphatase domains of protein tyrosine phosphatases.
6. The antibody according to any of claims 1-5, which is generated using a polypeptide that is encoded by a nucleotide sequence set out in SEQ ID NO: 1.
7. The antibody according to any of claims 1-6 wherein the antibody is a monoclonal antibody.
8. The antibody according to any of claims 1-7 wherein the antibody is generated using a fusion protein comprising a protein tyrosine phosphatase domain and another protein or a polypeptide, as an immunogen.
9. The antibody according to any of claims 1-7 wherein the antibody is generated using a GST-LAR phosphatase domain fusion protein as an immunogen.
10. The antibody according to claim 9 wherein the GST-LAR phosphatase domain fusion protein is produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours; and isolating the fusion protein from the culture fluid and/or bacterial cells.
11. The antibody according to claim 10 wherein the GST-LAR phosphatase domain fusion protein is further purified based on an affinity to a support carrying glutathione, and the elution of said fusion protein from the support is performed by boiling in the presence of a detergent.

12. The antibody according to any of claims 8-11 wherein screening of the antibody that was generated using the fusion protein as an immunogen is performed using said fusion protein.
13. A monoclonal antibody having specificity to an intracellular domain of protein tyrosine phosphatase, which is produced by a hybridoma with Accession No. FERM BP-6344.
14. The antibody according to any of claims 7-13 having a molecular weight of about 146 kDa.
15. A hybridoma cell line that produces the monoclonal antibody according to any of claims 7-12.
16. A hybridoma cell line with Accession No. FERM BP-6344.
17. A method for generating an antibody according to any of claims 1-14 wherein a fusion protein comprising a protein tyrosine phosphatase domain and another protein or a polypeptide fragment is used as an immunogen.
18. A method for generating an antibody according to any of claims 1-14 wherein a GST-LAR phosphatase domain fusion protein is used as an immunogen.
19. The method according to claim 18 wherein the GST-LAR phosphatase domain fusion protein is produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours; and isolating the fusion protein from the culture fluid and/or bacterial cells.
20. The method according to claim 19 wherein the GST-LAR phosphatase domain fusion protein is further purified based on an affinity to a support carrying glutathione, and the elution of said fusion protein from the support is performed by boiling in the presence of a detergent.
21. The method according to any of claims 17-20 wherein screening of the antibody that was generated using the fusion protein as an immunogen is performed using said fusion protein.
22. A method for isolating a novel protein tyrosine phosphatase comprising a step of screening a protein tyrosine phosphatase, wherein the antibody according to any of claims 1-14 is used in said step of screening.
23. The method according to claim 22 wherein said screening is performed by expression screening of a cDNA library.
24. A method of quantitative determination of protein tyrosine phosphatase and/or protein tyrosine phosphatase derived molecules comprising a step of:
 - determining an amount of protein tyrosine phosphatase protein and/or a fragment or a polypeptide that comprises at least a part of an intracellular domain of protein tyrosine phosphatase, which is contained in a test sample using the antibody according to any of claims 1 to 14.
25. The method according to claim 24 wherein the antibody is used in any of immunoblotting, immunoprecipitation and ELISA.
26. A method for quantitative determination of protein tyrosine phosphatase and/or protein tyrosine phosphatase derived molecules comprising steps of
 - isolating protein tyrosine phosphatase and/or a fragment or a polypeptide that comprises at least a part of an intracellular domain of protein tyrosine phosphatase, from a test sample using the antibody according to any of claims 1-14; and
 - measuring an activity of the isolated protein, fragment or polypeptide.
27. The method according to claim 26 wherein affinity chromatography and/or immunoprecipitation by using a support that was bound with the antibody are utilized in said isolation step.
28. A method for producing protein tyrosine phosphatase and/or protein tyrosine phosphatase derived molecules comprising a step of:

isolating protein tyrosine phosphatase protein and/or a fragment or a polypeptide that comprises at least a part of an intracellular domain of protein tyrosine phosphatase using the antibody according to any of claims 1-14.

29. The method according to claim 28 wherein affinity chromatography and/or immunoprecipitation by using a support
5 that was bound with the antibody are utilized in said isolation step.

30. A method for identifying the presence of protein tyrosine phosphatase and/or protein tyrosine phosphatase derived molecules within tissue comprising a step of:

10 performing immunohistological examination using the antibody according to any of claims 1-14 to detect protein tyrosine phosphatase protein and/or a fragment or a polypeptide that comprises at least a part of an intracellular domain of protein tyrosine phosphatase.

15

20

25

30

35

40

45

50

55





Fig.1




Fig.2




Fig.3




Fig. 4




Fig. 5




Fig. 6




Fig.7




Fig.8

LAR : SNLEVNKPKNRYANVIAVDHSRVILTSIDGVPGSDYINANYIDGYRKONAYIATQGPLPE 60
 CD45 : ARKPFNQKNRYVDILPYDYNRVELSEINGDAGSNYINASYIDGFKEPRKYIAAQGRDE 60
 * * * * *
 (1) (2)
 LAR : TMGDFWRMVWEQRTATVVMTRLEEKSRV KCDQYWFAR—GTETCGLIQVTLLDTVELAT 118
 CD45 : TVDDFWRMIEQKATVIIVMTRCEEGRNKCAEYWF SMEEGTRAFGDVVVKINQHKRCPD 120
 * * * * *
 (3)
 LAR : YTVRTFA—LHKSGSSEKRELRFQFMAMPDHGVPEYPTPILAFRRVKACNPLDAGPMVV 177
 CD45 : YIIQKLNIVNKEKATGREVTHIQFTSMPDHGVPEDPHLLKLRRRVNAFSNFFSGPIVV 180
 * * * * *
 (4)
 LAR : HCSAGVGRTCFIVIDAMLERMKHEKTVDIYGHVTCMRSQRNYMVQTEDQYVFIHEALLE 237
 CD45 : HCSAGVGRTCYIGIDAMLEGLEAENKVDVYGYVVKLRRQRCLMVQVEAQYILIHQALVE 240
 * * * * *
 LAR : AATCGHTEVPARNLYAHIQKLCQVPPGESVTAMELEFKLLASSKAHTRFISANLPCNKF 297
 CD45 : YNQFGETEVNLSLHPYLHNMKRDPPEPSPLEAEFQRLPSYRSWRTQHIGNQEE—NKS 299
 * * * * *
 LAR : KNRLVNIMPYELTRVCL—————QPIRCVEGSDYINASFLDGYRQQK 338
 CD45 : KNRNSNVIPIYDYNRVPLKHELEMSKESEHSDSESSDDSDSEEPSKYINASFIMSYWKPE 359
 * * * * *
 (1) (2)
 LAR : AYIATQGPLAESTEDFWRLWEHNSTIIVMLTKLREMGREKCHOYWFPAERSARYQYFVD 398
 CD45 : VMIAAQGPLKETIGDFWQMIFQRKVVIIVMLTELKHGDQEIFCAQYWGEGKQT—YGDIEVD 418
 * * * * *
 (3)
 LAR : PMAEYNMPQYILREFKVTDARDGQSRTIROFQFTDWPEQGVPKTGEGFIDFIGQV—— 453
 CD45 : LKDTDKSSTYTLRVFELRHSKRKDSRTVYQYQYTNWSVEQUPAEPKELISMIQVVKQLP 478
 * * * * *
 (4)
 LAR : —HKTKEQFGQDQPIVHCSAGVGRTCVFITLSIVLERMRYEGVVDMFQTVKTLRTQRP 510
 CD45 : QKNSSEGNKHHKSTPLLHCRDGSQQTGIFCALLNLLSAETEEVVDIFQVVKALRKARP 538
 * * * * *
 LAR : AMVQTEDQYQLCYRAALEYLCGSDHYAT————— 538
 CD45 : GMVSTFEQQYQLYDVIASTYPAQNGQVKKNNHQEDKIEFDNEVDKVKQDANCVNPLGAPE 598
 * * * * *
 LAR : —————
 CD45 : KLPEAKEQAEGSEPTSGTEGPEHSVNGPASPALNQQS 639

Fig. 9




Fig. 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP99/03656

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.⁶ C07K16/18, C12N5/20, C12P21/08, G01N33/53, G01N33/577, C12N15/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.⁶ C07K16/18, C12N5/20, C12P21/08, G01N33/53, G01N33/577, C12N15/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE (STN), Genbank/EMBL/DDBJ/GeneSeq

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Wei-Ren ZHANG et al., "Molecular cloning and expression of a unique receptor-like protein-tyrosine-phosphatase in the leucocyte-common-antigen-related phosphatase family", Biochem. J. (1994), Vol. 302, No. 1 p.39-47	1-30
A	Michel Streuli et al., "A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen", J. Exp. Med. (1988), Vol. 168, No. 5 p.1553-1530	1-30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
18 October, 1999 (18. 10. 99)

Date of mailing of the international search report
26 October, 1999 (26. 10. 99)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)